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ABSTRACT 
 
In cancer, loss of intercellular contact contributes to tumour progression and 
invasion.  Desmosomal cadherins are essential constituents of desmosomes 
– intercellular junctions that confer significant adhesive strength to epithelial 
tissues and cardiac muscle.  Although changes in desmosomal components 
have been noted in a variety of cancers previously, this investigation has 
shown for the first time altered desmocollin expression in colorectal cancer.   
Real-time PCR and western blotting were used to assess desmocollin 
expression in a series of colorectal cancer and matched normal tissue 
samples.  Loss of desmocollin 2 expression was observed in the cancer 
samples.  In addition, de novo expression of desmocollins 1 and 3, which are 
not normally expressed in the colon, was observed.  Desmoglein gene 
expression was also altered in the cancer samples. Although classical 
cadherin switching is a hallmark of the epithelial-mesenchymal transition, 
desmocollin switching has not previously been reported.   
Further experiments, to investigate the effect of loss of desmocollin 2 and 
desmoglein 2 on the behaviour of cultured cells were performed.  In addition, 
experiments were carried out to identify those transcription factors that 
regulate desmosomal cadherin gene expression in the colon.  Transcription 
factors of the CCAAT/enhancer-binding proteins family act as transcriptional 
activators of desmosomal cadherin promoters in colonic cells.    
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CHAPTER 1 
INTRODUCTION 
 
1.1 Colorectal Cancer  
 
1.1.1 Epidemiology 
Colorectal cancer (CRC) is a major cause of mortality and morbidity in the 
United Kingdom and other parts of the developed world (reviewed by Parkin, 
Bray et al. 2005).  It is the third most common cause of cancer death in the 
UK after lung and prostate cancer in men and after lung and breast cancer in 
women (Westlake and Cooper 2008). Over 30,000 new cases were 
diagnosed in  England in 2006, with more than 90% of these being in the over 
55 years age-group (Cancer Statistics Registrations 2006).  Whilst the 
incidence of colorectal cancer has remained largely stable over the past 
decade, mortality rates continue to fall due to improved diagnosis and 
treatment.  However, with the implementation of the National Health Service 
Bowel Cancer Screening Programme, it is likely that initially the incidence of 
colorectal cancer will increase, but deaths from colorectal cancer will be 
avoided as it will be diagnosed at an earlier stage.  
  
Colorectal cancer incidence and mortality are both higher in men than women.  
Age-standardised rates of colorectal cancer are higher in males (19.1 per 
100,000) than females (14.4 per 100,000) globally (Boyle and Leon 2002).  
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Incidence of CRC is highest in the United States of America, Canada, Japan 
and New Zealand (Parkin, Bray et al. 2005) and migration studies have shown 
the environmental factors result in migrants acquiring similar risk to the local 
population (McCredie, Williams et al. 1999).   
 
1.1.2 Aetiology 
Although the exact cause of colorectal cancer is not yet fully understood, both 
environmental and genetic factors play significant roles in the development of 
these tumours. 
 
1.1.2.1 Acquired Risk Factors for Colorectal Cancer 
Diet may influence the development of colorectal neoplasia through acting 
directly at the gut mucosa-lumen interface, or indirectly by changing the 
metabolism of key nutrients, hormones and growth factors throughout the 
body.  A number of different foodstuffs have been implicated in the 
development of colorectal neoplasia but overall the diet of the westernised 
world seems to be instrumental (Dixon, Balder et al. 2004). The Second 
Report of the World Cancer Research Fund concluded that high red meat and 
processed meat intake was convincingly implicated in colorectal 
tumourigenesis, whereas dietary fibre, garlic, milk and calcium probably 
protect against CRC and fruit and vegetables, folate-rich foods, vitamin D or 
selenium may protect against CRC (World Cancer Research Fund / American 
Institute for Cancer Research 2007).  Furthermore, a recent study has shown 
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recurrence and survival rates to be significantly worse in colorectal cancer 
patients with less fibre, more fat and more sugar in their diets (Meyerhardt, 
Niedzwiecki et al. 2007). Murine models have demonstrated that when fed a 
westernised diet high in fat, but low in fibre, folate, calcium, and vitamin D, 
tumours could be induced in normal C57B1/6 mice without carcinogen 
exposure (Newmark, Yang et al. 2001).  In addition, colonic neoplasia can be 
prevented by elevating dietary calcium and vitamin D in the westernised diet 
(Yang, Kurihara et al. 2008).   
 
The strongest evidence exists in relation to high levels of red and processed 
meat consumption.  One large meta-analysis, including 26 studies involving a 
total of over 15,000 subjects, demonstrated a 20% increased risk of 
developing colorectal cancer in the group with the highest consumption when 
compared to that with the lowest (Huxley, Ansary-Moghaddam et al. 2009). In 
addition, a high beef diet induced significantly more tumours in ApcMin 
(Multiple intestinal neoplasia) mice (Mutanen, Pajari et al. 2000) and has been 
implicated in tumour formation in rodents  and humans (Ferrucci, Sinha et al. 
2009). Various mechanisms for the tumourigenic role of meat consumption 
have been proposed,  including the formation of meat mutagens, such as 
heterocyclic amines, which are generated by cooking meat at high 
temperatures (Sinha, Rothman et al. 1998) and the alteration of protein kinase 
C (PKC) levels in rat colonic mucosa (Pajari, Oikarinen et al. 2000). 
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Fruit and vegetable intake was previously thought to have a protective role 
against colorectal cancer.   The Nurses’ Health Study showed there was no 
association between colon cancer and fruit and vegetable consumption 
(Willett, Stampfer et al. 1990).  The role of fibre in colorectal tumourigenesis 
has been extensively investigated. Several meta-analyses have been 
performed on data from case-control studies.  Young et al have summarised 
these and concluded that  there is a consistent protective effect from fibre and 
consumption of 30g per day reduces the risk of developing colorectal cancer 
by 50% (Young, Hu et al. 2005).  Prospective colorectal cancer and polyp 
prevention trials have failed to demonstrate the benefit of fibre as a primary 
prevention tool but such studies have been limited by short follow up periods 
(Asano and McLeod 2002).  Initially it was proposed that fibre provided stool 
bulk and volume and decreased transit time, reducing the exposure time of 
the colonic mucosa to carcinogens (Burkitt 1971).  Other mechanisms 
involving fermentation (increased production of short chain fatty acids, 
reduced solubility of bile salts), prebiotic action of gut flora and whole-body 
metabolism (reduced insulin resistance) have now been recognised (Kim 
2000).  In conclusion, although the exact roles and relative impact of 
individual macro- and micro-nutrients on the development of colorectal cancer 
has yet to be fully elucidated, the Western diet confers an increased risk of 
developing colorectal adenomas and carcinomas.   
 
Physical activity appears to have a protective effect against colorectal cancer 
(Huxley, Ansary-Moghaddam et al. 2009) with stronger evidence for its role in 
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colon rather than rectal cancer.  Aside from weight control, the mechanisms 
through which activity reduces colorectal cancer risk include decreased 
gastrointestinal transit time, thus reducing exposure time to carcinogens, 
altered prostaglandin secretion and bile acid metabolism (Friedenreich and 
Orenstein 2002).  Several studies have shown an increased risk of colorectal 
cancer with obesity.  The association appears to be stronger for men than 
women and colonic rather than rectal lesions (Moghaddam, Woodward et al. 
2007).  The excess of obesity-related cancers seen in men appears to be due 
at least in part to the central distribution of fat.  Women are more frequently 
‘pear-shaped’ (gluteofemoral fat distribution) but also showed a positive 
association of colon cancer with increasing waist-to-hip ratio (MacInnis, 
English et al. 2006).  Data from the Framingham cohort also concluded that 
waist circumference was a stronger predictor of lifetime risk of developing 
colon cancer than body mass index (Moore, Bradlee et al. 2004).   
 
Physical inactivity, central adiposity and obesity all result in high levels of 
insulin production, as do type II diabetes mellitus and hypertriglyceridaemia.  
(McKeown-Eyssen 1994).  Conditions associated with high levels of 
circulating insulin are at increased risk of colorectal tumourigenesis.  (Tran, 
Medline et al. 1996).  Insulin acts to increase levels of Insulin-like Growth 
Factor (IGF)-1 which inhibits apoptosis and stimulate proliferation of colon 
cancer cells.  Acromegaly and greater adult height are also associated with 
raised levels of IGF-1 and are associated with increased CRC risk 
(Giovannucci 2001).  
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Although early studies investigating a relationship between cigarette smoking 
and colorectal cancer failed to demonstrate a link, more recent evidence from 
large meta-analyses suggests that in fact, smoking is associated with both 
adenoma (Botteri, Iodice et al. 2008) and colorectal tumour formation (Liang, 
Chen et al. 2009). Tobacco smoking is well known to release a range of 
carcinogens which reach the colonic mucosa both via the bloodstream and 
through digestion. A recent review of the evidence has indicated that daily 
cigarette consumption; number of pack-years; age of initiation and duration of 
smoking habit are all factors adding to the increased risk of colorectal cancer 
in smokers, which is thought to contribute in up to 20% of cancers (Chan and 
Giovannucci 2010).  Cigarette smoking appears to be more strongly 
associated with microsatellite instability in colorectal cancer, in particular with 
CIMP-positive (CpG Island Methylator Phenotype) tumours with BRAF 
mutations – a picture observed with the sessile serrated adenoma pathway 
(Slattery, Curtin et al. 2000; Samowitz, Albertsen et al. 2006). 
 
1.1.2.2 Co-Morbid Conditions      
The association between inflammatory bowel disease (IBD) and CRC is well 
recognised, having been first described by Crohn and Rosenberg in 1925 
(Crohn and Rosenberg 1925).  Colorectal cancer arising against a 
background of either Crohn’s disease or Ulcerative Colitis represents for only 
1-2% of all cases of CRC but is responsible for the death of 10-15% of 
patients with inflammatory bowel disease (Munkholm 2003).  The affected 
patients are younger than those with sporadic cancers, with one meta-
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analysis giving the average age at diagnosis as 43.2 years (Eaden, Abrams et 
al. 2001).      This, and other studies have concluded that extensive disease 
(Ekbom, Helmick et al. 1990) and duration of more than 10 years  are the 
most important risk factors for the development of colitis-associated cancer 
(Ekbom, Helmick et al. 1990), as well as primary sclerosing cholangitis, a 
family history of colorectal cancer and the degree of inflammation (Lakatos 
and Lakatos 2008). 
Numerous studies have investigated the relationship between gallstones, 
cholecystectomy and the development of colorectal adenomas and cancer.  
This has been difficult to characterise as there many risk factors that are 
common to both, in particular, diet.   A large prospective study that stratified 
for such confounding variables found a relative increased risk of up to 1.58 
times when compared to the control group (Schernhammer, Leitzmann et al. 
2003).  Various hypotheses have been postulated including altered bile salt 
metabolism and increased faecal fat content in cholecystectomised patients 
(Morvay, Szentleleki et al. 1989; Zuccato, Venturi et al. 1993). 
 
Several studies have concluded that type 2 diabetes results in an increased 
risk of colorectal cancer of around 30% (Larsson, Orsini et al. 2005) and also 
an increased risk of mortality from colorectal cancer (Jiang, Ben et al. 2011). 
This has been attributed to the effects of hyperinsulinaemia and insulin 
resistance (reviewed by Giovannucci 1995; Giovannucci 2001).  
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Carcinoma development following urinary diversion into the sigmoid colon is a 
well-recognised long term complication of ureterosigmoidostomy.  Although 
largely historical now as this procedure has been superseded by other forms 
of bladder reconstruction, it is important to recognise this as a cause of 
colorectal neoplasia as it has a latent period of 20-30 years and an incidence 
of up to 2.5% (Kälble, Hofmann et al. 2011). 
 
1.1.2.3 Inherited Colorectal Cancer Syndromes 
Approximately 5% of all cases of colorectal cancer can be ascribed to 
syndromes that have been characterised by their genetic alteration, clinical 
manifestations or both (Table 1.1).  However, it has been suggested that in up 
to 30% of all cases of colorectal cancer inherited factors may be involved, 
although the genetic events involved have not been fully elucidated as yet 
(Jasperson, Tuohy et al. 2010).   
 
The recognised syndromes can be divided into those exhibiting multiple polyp 
formation and those which do not.  Although the colorectal tumours that 
feature in Lynch syndrome (also known as Hereditary Non-Polyposis 
Colorectal Cancer, HNPCC) still arise in adenomas, polyposis is rare.  It is the 
most common form of inherited colorectal cancer, accounting for up to 5% of 
cases (Lynch and de la Chapelle 1999; Hampel, Frankel et al. 2008), with a 
lifetime risk of developing a colorectal cancer of 70%, as well as other cancers 
(Stoffel, Mukherjee et al. 2009). Patients in this group are often younger, with 
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cancers and polyps that are located more proximally in the colon and are at 
risk of extracolonic malignancy (see Table 1.1). They exhibit high levels of 
microsatellite instability, as a result of germline mutations in the mismatch 
repair genes (hMLH1, hMLH2, hMSH6, hPMS2, EpCAM) (Söreide, Janssen 
et al. 2006; Jasperson, Tuohy et al. 2010).  Clinical guidelines (Amsterdam 
criteria I and II) are now used in conjunction with genetic information (revised 
Bethesda criteria) to identify at-risk individuals who require further 
investigation (Umar, Boland et al. 2004).   
 
Familial adenomatous polyposis (FAP) accounts for <1% of all colorectal 
cancer cases.  It arises due to mutations of the APC  (adenomatous polyposis 
coli) gene on chromosome 5q (Bodmer, Bailey et al. 1987; Groden, Thliveris 
et al. 1991) and results in the development of thousands of adenomas 
throughout the colon and rectum.  These develop in early adolescence and 
the risk of developing an associated cancer is 100% if untreated. The mean 
age of developing colorectal cancer in these individuals is 39 years.  
Attenuated FAP exhibits far fewer polyps (average number is 30), with a 
lifetime cancer risk of 69% (Burt, Leppert et al. 2004).  MUTYH-associated 
polyposis (MAP) is a genetically distinct condition with a phenotype similar to 
FAP.  It arises due to biallelic mutations of the MUTYH gene on chromosome 
1, resulting in the development of polyposis by the fourth decade and a 
lifetime risk of colorectal cancer of 100% by 60 years of age (Cleary, 
Cotterchio et al. 2009). 
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Peutz-Jeghers syndrome and juvenile polyposis syndrome both result in the  
development of hamartomatous polyposis with increased risk of colorectal 
cancer.  These patients often present in adolescence or young adulthood with 
symptoms from extracolonic manifestations of these syndromes (listed in 
Table 1.1), with both conditions presenting a lifetime risk of colorectal cancer 
of 39%. 
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Table 1.1 Features of colorectal cancer syndromes 
Syndrome 
(inheritance pattern) 
Genes 
involved 
Type of cancer 
 
Other features 
Lynch syndrome (AD) hMLH1, 
hMLH2, 
hMSH6, 
hPMS2, 
EpCAM 
Colon, endometrium, 
stomach, pancreas, small 
bowel, ovary, 
hepatobiliary, kidney, 
CNS 
 
rare 
Familial adenomatous 
polyposis (AD) 
APC Colon, duodenum. 
stomach, pancreas, 
thyroid, liver, CNS 
Florid polyposis 
throughout colon and 
rectum, gastric and 
duodenal polyposis, 
CHRPE, epidermoid 
cysts, osteomas, desmoid 
tumours (Gardner 
syndrome) 
 
Attenuated FAP (AD) APC Colon, duodenum, thyroid <100 colonic polyps, 
upper GI polyps 
 
MUTYH-associated 
polyposis (AR) 
 
MUTYH Colon, duodenum <100 colonic polps, 
duodenal polyps 
Peutz-Jeghers 
syndrome (AD) 
STK11 Breast, colon, pancreas, 
stomach, ovary, lung, 
small bowel, uterine, 
testis 
 
Peri-oral pigmentation, GI 
hamartomas 
Juvenile polyposis 
syndrome (AD) 
SMAD4, 
BMPR1A 
Colon, stomach, 
pancreas, small bowel 
GI hamartomas, 
hereditary haemorrhagic 
telangiectasia, congenital 
defects 
 
Hyperplastic polyposis  colon Hyperplastic polyps, 
sessile serrated polyps 
 
AD, autosomal-dominant; AR, autosomal-recessive; CNS, central nervous 
system; FAP, familial adenomatous polyposis; CHRPE, congenital 
hypertrophy of the retinal pigment epithelium (adapted from Jasperson, Tuohy 
et al. 2010) 
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Once features of these distinct inherited colorectal cancer syndromes have 
been identified, genetic testing of the affected individual and at-risk relatives 
can be performed.  This allows screening colonoscopy and risk-reducing 
surgery to be performed.  Surveillance schedules vary according to the 
syndrome but would aim to start as a teenager or young adult or at least 5 
years younger than the youngest affected relative. 
 
1.2 Models of colorectal cancer pathogenesis 
 
1.2.1  The adenoma-carcinoma sequence 
It is now widely regarded that majority of sporadic colorectal cancers arise in 
adenomatous polyps, which may be situated anywhere within the colon or 
rectum (Leslie, Carey et al. 2002).  However, not all adenomas will develop 
into cancers and when they do, it is usually a slow process that takes many 
years.  Although there are no reliable criteria that can be used to predict which 
have malignant potential, a number of features have been recognised as risk 
factors for malignant transformation (Table 1.2) (Hardy, Meltzer et al. 2000). 
 
In 1990, Fearon and Vogelstein proposed a genetic model for colorectal 
tumourigenesis, in which the transition from normal mucosa to adenoma to 
carcinoma involved the stepwise accumulation of genetic events (Fearon and 
Vogelstein 1990).  A further intermediary step was subsequently identified 
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when aberrant crypt foci were shown to be the precursors to the development 
of adenomas (Takayama, Katsuki et al. 1998) (see Fig 1.1).   
 
Fearon acknowledged it is the accumulation of genetic alterations rather than 
the order, and numerous other events have been observed and added to the 
model since it was originally described.  Two main molecular pathways have 
been described:  chromosomal instability and microsatellite instability.  More 
recently it has been recognised that not all colorectal cancers arise through 
this traditional model, which has resulted in an additional pathway being 
described, the serrated pathway. 
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Table 1.2 Features of colonic polyps associated with malignant 
transformation 
 
High Risk Low Risk 
 
Large size (>1.5cm) 
 
Small size (<1cm) 
Sessile or flat Pedunculated 
Severe dysplasia Mild dysplasia 
Presence of squamous metaplasia No metaplasia 
Villous architecture Tubular architecture 
Polyposis Single polyp 
  
(adapted from Hardy, Meltzer et al. 2000) 
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Fig 1.1 The adenoma-carcinoma sequence 
 
 
(adapted from Söreide, Janssen et al. 2006) 
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1.2.2 Chromosomal instability 
The chromosomal instability pathway is seen in about 75% of sporadic 
cancers and involves allelic losses (loss of heterozygosity (LOH) at 17p and 
18q) and chromosomal alterations which result in tumour aneuploidy (in 
particular, at chromosome 5q). 
 
Although germline mutations of the APC gene are responsible for the 
development of FAP, somatic mutations of this gene or allelic losses at 5q 
have been identified in 70-80% of sporadic colorectal tumours (Vogelstein, 
Fearon et al. 1988; Powell, Zilz et al. 1992). Mutation of the APC gene on 
chromosome 5q takes place early in the adenoma-carcinoma pathway 
(Powell, Zilz et al. 1992), as the majority of sporadic adenomas, as well as 5% 
of aberrant crypt foci have demonstrated this loss (Otori, Konishi et al. 1998).  
In addition, inactivation of the APC gene by promoter methylation has been 
demonstrated in 18% of colorectal cancers (Esteller, Sparks et al. 2000) 
The APC protein is a large multi-functional protein with roles in many varied 
cellular processes (Pino and Chung 2010), but its role in the Wnt signalling 
pathway is key to the development of colorectal cancer (Munemitsu, Albert et 
al. 1995).  The functional, wild-type APC protein forms a complex with Wnt 
components, β-catenin and GSK-3β (Rubinfeld, Souza et al. 1993; Rubinfeld, 
Albert et al. 1996), allowing excess β-catenin to be broken down via 
ubiquitination and proteasomal degradation.  However, mutant APC proteins 
often have impaired β-catenin binding ability (Kinzler and Vogelstein 1996), 
resulting in the intra-cellular accumulation of β-catenin (Munemitsu, Albert et 
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al. 1995).  This then translocates to the nucleus, where it initiates 
transcriptional activation through its interaction with the TCF/LEF family of 
transcription factors (Mann, Gelos et al. 1999).   Increased β-catenin/TCF 
mediated transcriptional activity has been observed not only with APC 
mutations, but also with mutations of the β-catenin gene, providing another 
mechanism through which this system can be activated (Morin, Sparks et al. 
1997; Sparks, Morin et al. 1998). 
 
Mutations of the K-ras oncogene on chromosome 12p are also thought to take 
place early in the development of colorectal cancer.  These mutations have 
been observed with similar frequency in carcinomas and large adenomas, at 
around 30-40% (Bos, Fearon et al. 1987; Bos, Fearon et al. 1987; Forrester, 
Almoguera et al. 1987), but are less commonly seen in small adenomas 
(Scott, Bell et al. 1993).  These mutations result in a constitutively active ras 
protein, which is involved in signal transduction of a variety of processes that 
regulate normal proliferation and differentiation (reviewed in Pino and Chung 
2010). Furthermore, K-ras is a down stream effector of the epidermal growth 
factor receptor (EGFR) pathway.  The EGFR is a tyrosine kinase receptor that 
is overexpressed in up to 80% of colorectal cancers and is associated with 
poor prognosis. Chemotherapeutic agents that inhibit EGFR overexpression 
are used in the treated of advanced colorectal cancer.  K-ras mutation may be 
used to predict response to treatment. 
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The tumour suppressor gene p53 is located on chromosome 17p and is 
widely regarded as the ‘guardian of the genome’.  It is the regulator of 
numerous functions including apoptosis, cell cycle control and differentiation 
(Lane 1992).  Loss of p53 function is thought to contribute to the transition 
from adenoma to carcinoma as missense mutations or 17p allelic loss are far 
less frequently observed in adenomas than colorectal cancers (Leslie, Carey 
et al. 2002). 
 
Loss of heterozygosity at chromosome 18q is a common event in colorectal 
cancer, with changes identified in 70% of sporadic tumours,  increasing in 
frequency with advanced stage (Fearon and Vogelstein 1990).  This led to a 
search for a potential tumour suppressor gene within this region.  The original 
candidate, DCC (Deleted in Colorectal Carcinoma) (Fearon, Cho et al. 1990) 
has subsequently been refuted in this role (Cho, Oliner et al. 1994).  SMAD2 
and SMAD4 also made attractive candidates for the role as they have been 
implicated in a variety of human cancers (Riggins, Kinzler et al. 1997) and act 
as mediators of TGFβ-signalling (Zhou, Buckhaults et al. 1998), a mechanism 
also implicated in the microsatellite instability pathway of colorectal 
carcinogenesis (Parsons, Myeroff et al. 1995).  However, mutations in these 
genes were seen in only 10-20% of colorectal tumours examined for this 
(Takagi, Koumura et al. 1998).  The Cables gene also maps to chromosome 
18q and through allelic loss and promoter methylation, exhibits reduced 
expression in 70% of sporadic colorectal cancers (Park do, Sakamoto et al. 
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2007).  Although LOH at 18q is a common event in colorectal tumourigenesis, 
no single gene within this region has been identified as the main target. 
The COX2 gene on chromosome 1q is overexpressed in 40% of adenomas 
and 85% of cancers (Eberhart, Coffey et al. 1994).  In addition, one study 
found that COX2 expression correlated with increasing dysplasia in 
adenomas, underlying its importance in the adenoma-carcinoma sequence 
(Sato, Yoshinaga et al. 2003).  It mediates its tumourigenic effects via 
prostaglandin E2 in response to a variety of growth factors and inflammatory 
mediators.   Blockade of this pathway has shown to reduce adenoma 
formation in an APC knockout mouse model (Oshima, Murai et al. 2001), as 
well as reduce adenoma recurrence in clinical trials (Arber, Eagle et al. 2006), 
which generated great enthusiasm for these agents in chemoprevention.   
Despite a wealth of evidence to support the role of aspirin and COX2 
inhibitors in colorectal cancer prevention, concern about side effects has held 
back their use in the general public at present. 
 
1.2.3  Microsatellite Instability 
Microsatellites are short repetitive dinucleotide sequences that occur 
throughout the genome. Microsatellite instability (MSI) arises due to defects in 
DNA mismatch repair genes (eg hMLH1, hMSH2, hMSH6, hPMS2). These 
genes normally correct errors that accumulate during DNA replication, 
however, persistence of these replication errors results in frameshift mutations 
and base-pair substitutions.  This mechanism is thought to be responsible for 
the inherited colorectal cancers seen in Lynch syndrome patients, with 90% of 
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patients having a germline mutations in hMLH1 and hMSH2 (Söreide, 
Janssen et al. 2006). Microsatellite instability has also been detected in 12-
28% of sporadic colorectal cancers (Ionov, Peinado et al. 1993; Thibodeau, 
Bren et al. 1993) but takes place via a different mechanism – promoter 
silencing by methylation (Kane, Loda et al. 1997). The CpG Island Methylator 
Phenotype (CIMP) has been observed in up to 50% of sporadic colorectal 
cancer (Toyota, Ahuja et al. 1999).  Methylation is also associated with 
increasing age and as a response to inflammation (reviewed by Boland and 
Goel 2010).   
 
The errors that persist as a consequence of defective mismatch repair result 
in the accumulation of mutations of other genes known to play a role in 
colorectal cancer.  However, genes other than the DNA mismatch repair 
genes, that also exhibit microsatellite instability, have been implicated in the 
development of this form of colorectal cancer, eg transforming-growth factor 
β-type II receptor and BAX.  Alterations in the transforming-growth factor β-
type II receptor have been demonstrated in 90% of Lynch syndrome tumours 
(Parsons, Myeroff et al. 1995), which acts as a tumour suppressor in the 
colonic epithelium (Markowitz, Wang et al. 1995).  BAX gene expression is 
altered in 35% of tumours with microsatellite instability, resulting in defective 
apoptosis mechanisms (Trojan, Brieger et al. 2004; Fernandez-Peralta, Nejda 
et al. 2005). 
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The molecular differences between the chromosomal instability pathway and 
the microsatellite instability pathway manifest themselves at both a clinical 
and pathological level.  Microsatellite instability is more common in female 
patients, as well as in tumours in the proximal colon. Both synchronous and 
metachronous tumours are more common in microsatellite unstable patients. 
Despite displaying features associated with poor prognosis (Wright, Dent et 
al. 2000), these patients appear to have improved survival compared to 
chromosomal instability tumours (Gryfe, Kim et al. 2000; Popat, Hubner et al. 
2005). 
 
1.2.4  Serrated pathway of colorectal tumourigenesis 
Although the majority of colorectal cancers arise in adenomas, an alternative 
mechanism has been identified – the serrated pathway, which is thought to be 
involved in the development of up to 20% of sporadic cancers (Bauer and 
Papaconstantinou 2008).  The precursor lesions, which include traditional 
serrated adenoma (TSA), mixed polyp and sessile serrated adenoma (SSA), 
are morphologically similar to a hyperplastic polyp, but have malignant 
potential.  The molecular pathways and the natural history of these polyps 
have not been fully elucidated, but has been shown to involve oncogenic 
activation of mitogen-activated protein kinase (MAPK) signalling pathway.  
Sessile serrated adenomas also exhibit microsatellite instability and CpG-
island methylator phenotype (Chan, Zhao et al. 2003), along with BRAF 
mutations (Davies, Bignell et al. 2002). They seem to adopt a similar clinical 
picture to other tumours exhibiting microsatellite instability, in that they are 
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more commonly observed in middle-aged women with right-sided tumours.  
The addition of BRAF mutation does not seem to affect the prognostic 
advantage of microsatellite unstable tumours (Samowitz, Sweeney et al. 
2005).  The traditional serrated adenoma accounts for <1% of all colorectal 
polyps.  
 
 1.3 Role of cell adhesion in the adenoma-carcinoma sequence 
Stable intercellular adhesion is essential for tissue integrity, both during 
development and post-embryonic life.  In cancer, loss of cell-cell contacts 
allows tumours to progress, invade surrounding tissues and eventually 
metastasise.  Cell adhesion can be mediated by various junctional complexes, 
including adherens junctions (AJ), desmosomes, gap junctions and tight 
junctions.  Adherens junctions and desmosomes share both structural and 
functional similarities, although these have been more extensively studied in 
adherens junctions.  Alterations in AJ components are well recognised in 
several diseases, including cancer.  Loss of E-cadherin function due to 
germline mutations results in hereditary diffuse gastric cancer demonstrating 
its role as a true tumour suppressor gene (Guilford, Hopkins et al. 1998).  
Loss of function has been demonstrated in many other cancers, including 
breast, prostate, colon, kidney and skin (Semb and Christofori 1998).  Loss of 
E-cadherin is a late event in the adenoma-carcinoma sequence contributing to 
the tumour’s ability to invade and metastasise (Tsanou, Peschos et al. 2008).  
Another key component of AJs involved in cancer is β-catenin.   β-catenin 
acts as a transcriptional activator in the wnt signal transduction pathway and 
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failure to degrade β-catenin, as a result of mutations in the tumour suppressor 
adenomatous polyposis coli (APC), is associated with tumours in a number of 
different tissues.  
 
Like AJs, desmosomes also contain cadherins and armadillo proteins as well 
as other proteins, including desmoplakin.  Although no mutations in 
desmosomal components have been identified thus far it has been proposed 
that desmosomes could also have a role in the development of cancer.  
 
1.4 Desmosomes         
Desmosomes are intercellular junctions that mediate adhesion by linking the 
intermediate filament networks of adjacent cells. They are found in all 
epithelial tissues, as well as cardiac muscle and the follicular dendritic cells of 
lymph nodes (Schmidt, Heid et al. 1994).  Desmosomes confer strong cell-cell 
adhesion and are particularly abundant in tissues that experience mechanical 
stress, e.g. stratified epithelia and cardiac muscle. Desmosomal composition 
not only varies between different tissues but also within the same cell type 
(Getsios, Huen et al. 2004).  
 
1.4.1 Desmosome structure  
At an ultrastructural level, desmosomes consist of an electron dense 
cytoplasmic plaque at either side of a central core, which occupies the gap 
between adjacent cells (Green and Gaudry 2000). The cytoplasmic region is 
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further divided into the outer and inner dense plaque, which provides the 
location for the insertion of intermediate filaments.  Desmosomes confer 
structural continuity on entire tissues by linking the intermediate filament 
networks of all the cells in the tissue (Kowalczyk, Bornslaeger et al. 1999).  
Desmosomes are complex, multimolecular structures that are made up of 
proteins that belong to one of three families: the desmosomal cadherins, the 
armadillo proteins and the plakins (Chidgey 2011).  The individual 
components may vary according to cell type, differentiation status and 
disease state. 
 
1.4.2 Desmosomal cadherins 
There are 2 types of desmosomal cadherin, desmocollin and desmoglein 
(Fig.1.2).  Seven desmosomal cadherins has been identified in humans so far. 
There are three desmocollins (DSC1-3) (Parker, Wheeler et al. 1991) 
(Kawamura, Watanabe et al. 1994), and four desmogleins (DSG1-4) (Koch, 
Walsh et al. 1990; Koch, Goldschmidt et al. 1991; Wheeler, Buxton et al. 
1991; Wheeler, Parker et al. 1991; Schafer, Koch et al. 1994; Kljuic, Bazzi et 
al. 2003).  Two further desmocollins have been identified in mice (Dsc5-6).  
Each desmosomal cadherin isoform is encoded by a distinct gene (Buxton, 
Cowin et al. 1993; King, Arnemann et al. 1993; Buxton, Wheeler et al. 1994) 
and these are clustered together at chromosome 18q12.1 (Hunt, Sahota et al. 
1999).  
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The individual desmosomal cadherin isoforms are expressed in in a cell-type 
and differentiation specific manner (Buxton, Cowin et al. 1993; Koch and 
Franke 1994) (Garrod, Chidgey et al. 1996). DSC2 and DSG2 are ubiquitous 
in all desmosome forming tissues, and have been identified in both simple 
and stratified epithelia, as well as cardiac myocytes and lymphoid tissue 
(Nuber, Schafer et al. 1995) (Schafer, Koch et al. 1994). In a simple (non-
stratified) epithelium such as the colon, the only desmocollins expressed are 
DSC2 and DSG2 (Schafer, Koch et al. 1994; Nuber, Schafer et al. 1995).  The 
expression of the other isoforms is mostly observed in stratified epithelia, such 
as the epidermis, oesophagus and cervix, whereby DSC3 and DSG3 
predominate in the basal layers and DSC1 and DSG1 are expressed in the 
more superficial, terminally-differentiated layers (Theis, Koch et al. 1993), 
(Nuber, Schafer et al. 1996), (North, Chidgey et al. 1996; Chidgey, Yue et al. 
1997) (Amagai, Koch et al. 1996) (Legan, Yue et al. 1994).  At the amino acid 
level, the desmocollin and desmoglein isoforms within a species share 51-
55% sequence identity and between different species, the individual isoforms 
appear to show up to 83% homology (Huber 2003). 
 
Desmosomal cadherins are transmembrane glycoproteins that consist of a 
transmembrane domain, which interacts with the desmosomal cadherins of 
the adjacent cell and a cytoplasmic portion, which interacts with the 
intermediate filament network through binding to plakoglobin, plakophilin and 
desmoplakin (Fig.1.3).  The desmosomal cadherins share some structural 
homology with the classical cadherins, especially in the extracellular domain 
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(Wheelock and Johnson 2003). The transmembrane portion consists of five 
extracellular repeats, with the one that is most proximal to the membrane 
termed the extracellular anchor (Green and Gaudry 2000). 
 
The desmocollins and desmogleins interact through the cell adhesion 
recognition sites in their extracellular domains (Runswick, O'Hare et al. 2001). 
The desmocollins and desmogleins bind in a heterotypic fashion (Chitaev and 
Troyanovsky 1997; Marcozzi, Burdett et al. 1998) and at least one 
desmocollin and one desmoglein are required to confer desmosomal 
adhesion (Tselepis, Chidgey et al. 1998).  Other studies have identified 
homophilic as well as heterophilic interactions, which appear to be isoform-
specific (Syed, Trinnaman et al. 2002) (Nie, Merritt et al. 2011). 
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Fig 1.2 Structure of desmosomal components 
 
a. Desmocollin 
 
       
      b. Desmoglein 
 
 
 
      c. Plakoglobin 
 
       
       
d.  Plakophilin  
 
 
 
e. Desmoplakin 
              
 
EC1-4, Extracellular repeat domain; EA, extracellular anchor; TM, 
transmembrane domain; IA, intracellular anchor; ICS, intracellular cadherin 
segment; IPL, intracellular proline-rich linker; RUD,repeat unti domain, DTD, 
desmoglein specific domain.  ‘a’ and ‘b’ indicate desmocollin splice variants.  
The blue box in the plakophilin sequence indicates a 61 amino acid sequence 
that introduces a bend in the Arm repeat domain. 
 
      
 
 
 
 
           
ICS         
 EC1     EC2     EC3    EC4      EA    TM IA 
 EC1     EC2      EC3     EC4     EA   TM   IA    ICS   IPL RUD  DTD 
‘a’ 
‘b’ 
     
              
 N-terminal                Armadillo repeats                               C-terminal 
           
 N-terminal                Armadillo repeats                               C-terminal 
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Distinction arises between the desmocollins and desmogleins in the 
intracellular domain.  They all contain an intracellular anchor domain adjacent 
to the membrane. The desmocollin cytoplasmic domain undergoes alternative 
splicing, to give two isoforms ‘a’ and ‘b’ (Fig 1.2).  The ‘a’ isoform has an 
intracellular cadherin segment (ICS) which provides a binding site for 
plakoglobin (Troyanovsky, Eshkind et al. 1993; Mathur, Goodwin et al. 1994; 
Chitaev, Averbakh et al. 1998).  The ‘b’ splice variant has a truncated ICS, so 
is unable to bind plakoglobin.  The role of the DSC ‘b’ isoform is unknown at 
this time.  As well as interacting with plakoglobin, the desmosomal cadherins 
bind plakophilins (Bonne, Gilbert et al. 2003; Gehmlich, Syrris et al. 2011).  
Desmogleins have a much more extensive cytoplasmic domain than the 
desmocollins (Fig 1.2), which has an additional intracellular proline-rich linker 
(IPL), a 29-amino acid repeat unit domain and a C-terminal glycine-rich 
terminal domain (Kowalczyk, Bornslaeger et al. 1999).  
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Fig 1.3 Structure of a desmosome 
 
 
 
 
PM, plasma membrane 
(adapted from Chidgey 2011)  
Extracellular region             Intracellular region         
Outer dense 
plaque                        
Inner dense 
plaque                        
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1.4.3 Armadillo proteins 
The armadillo family members plakoglobin (also known as γ-catenin) and 
plakophilins 1-3 are cytoplasmic desmosomal proteins.  They are 
characterised by their central domains, which consist of a series of imperfect 
42-amino acid repeats, known as Arm-repeats.  The Arm-repeat domain 
provides binding sites for both the desmosomal cadherins and desmoplakin 
(Troyanovsky, Chitaev et al. 1996; Kowalczyk, Bornslaeger et al. 1997; Huber 
2003). Evidence for the essential role of both plakoglobin and the plakophilins 
in the structure of desmosomes comes from the plakoglobin- and plakophilin 2 
null mouse models.  Knockout of either plakoglobin or plakophilin 2 results in 
embryonic lethality at 12-16 days as a result of desmosomal disruption in 
cardiac cells, leading to cardiac rupture and death (Ruiz, Brinkmann et al. 
1996; Achenbach, Brunner et al. 2003; Grossmann, Grund et al. 2004).  
    
In addition to its structural function, plakoglobin also plays a role in cellular 
signalling.  It shares significant homology with β-catenin, another armadillo 
family member, which has a well-established signalling role in the wnt 
pathway and consequently, colorectal cancer (Morin, Sparks et al. 1997; 
Morin 1999).  Whereas β-catenin is usually restricted to adherens junctions, 
plakoglobin can incorporate into both adherens junctions and desmosomes.  
As a result, it is able to mediate communication between these two types of 
junction and promote epithelial adhesion (Getsios, Huen et al. 2004).  
Plakoglobin is involved in signalling when it is not tethered to the structure of 
either of these cell junctions.  Like its homologue, β-catenin, plakoglobin is 
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able to activate TCF/LEF family of transcription factors, even in a β-catenin-
deficient cell line (Maeda, Usami et al. 2003).  In addition it has been shown to 
interfere with β-catenin proteasomal degradation (Salomon, Sacco et al. 
1997), thus increasing the cytoplasmic β-catenin pool. However, plakoglobin 
does not have the same potency as β-catenin to activate the TCF/LEF 
pathway (Simcha, Shtutman et al. 1998) and may in fact have act as a 
negative regulator of β-catenin signalling (Miravet, Piedra et al. 2002). 
Plakophilins may also have a signalling role in the wnt pathway as over-
expression of plakophilin 2 in colon carcinoma cells leads to an increase in β-
catenin/TCF signalling (Chen, Bonne et al. 2002). 
 
1.4.4 Desmoplakin 
Desmoplakin (DSP) is one of the obligatory proteins required to mediate 
desmosomal adhesion.  It has two isoforms (DPI and DPII) which arise 
through alternative splicing and differ only in the length of their rod domains.  
The N-terminal end of desmoplakin is able to bind to the armadillo proteins 
(Kowalczyk, Bornslaeger et al. 1997) whereas its C-terminal end interacts with 
the intermediate filament network (Kouklis, Hutton et al. 1994). 
 
1.4.5 Regulation of desmosomal gene expression 
Little is known about desmosomal gene expression but it is assumed to take 
place in a coordinated manner as all the desmosomal cadherin genes are 
tightly clustered together on chromosome 18 (Hunt, Sahota et al. 1999; 
Whittock, Hunt et al. 2000).  CCAAT/enhancer binding proteins (C/EBPs) 
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have been shown to regulate desmocollin 1 and desmocollin 3 gene 
expression in keratinocytes (Smith, Zhu et al. 2004).  In addition, CDX1 and 
CDX2 appear to control DSC2 expression in colonic cells (Funakoshi, Ezaki et 
al. 2008) and p53 plays a role in the regulation of DSC3 expression in breast 
cancer cells (Oshiro, Watts et al. 2003).  
 
1.4.6 Desmosomes and disease 
The importance of  desmosomes in tissue integrity has been illustrated by 
knockout mouse models. DSG2, desmoplakin, and plakoglobin null mice 
(Bierkamp, McLaughlin et al. 1996; Ruiz, Brinkmann et al. 1996; Gallicano, 
Kouklis et al. 1998; Eshkind, Tian et al. 2002) all resulted in embryonic 
lethality, demonstrating severe heart and skin defects.  The DSC1 and DSG3 
knockouts were both compatible with life but exhibited severe skin changes 
(Koch, Mahoney et al. 1997; Chidgey, Brakebusch et al. 2001). 
 
Both acquired and inherited disorders occur as a result of defective 
desmosomal adhesion.  The skin blistering disorders pemphigus vulgaris and 
pemphigus foliaceus are autoimmune diseases with pathogenic antibodies 
directed against DSG3 and DSG1 respectively (Amagai, Koch et al. 1996; 
Koch, Mahoney et al. 1997; Stanley and Amagai 2006). The exfoliative toxin 
produced by Staphylococcal aureus in staphylococcal scalded skin syndrome 
cleaves DSG1 in the suprabasal layers of the epidermis (Amagai, Matsuyoshi 
et al. 2000). 
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A number of conditions arise from inherited mutations in desmosomal genes.  
These generally affect either the heart or skin, and sometimes both (Chidgey 
2011).  For example mutations in any of the five desmosomal genes that are 
expressed in the heart (DSC2, DSG2, JUP, PKP2 and DSP)  can give rise to 
arrhythmogenic right ventricular dysplasia, a cause of sudden cardiac arrest 
and death, particularly in young adults (Awad, Calkins et al. 2008).  Mutations 
in the genes encoding plakoglobin and desmoplakin can give rise to Naxos 
disease and Carvajal syndrome respectively, characterised by palmoplantar 
keratoderma, woolly hair and heart disease (Chidgey, 2011).   
 
1.4.7 Desmosomes and cancer 
Altered expression of various desmosomal components has been 
demonstrated in cancer.  Loss of heterozygosity of chromosome 18q, in the 
region occupied by the desmosomal cadherin gene cluster, has been 
demonstrated in both head and neck cancers and oesophageal cancer 
(Karkera, Ayache et al. 2000; Takebayashi, Ogawa et al. 2000).  Decreased 
expression of DSG2 has been reported in gastric cancer (Biedermann, 
Vogelsang et al. 2005).  Similarly, loss of expression of DSC2 in colon cancer 
(Khan, Hardy et al. 2006) and DSC3 in breast cancer (Oshiro, Kim et al. 2005) 
has been reported.   Loss of individual desmosomal cadherins has been 
shown to correlate with invasion, metastasis and survival in oral cancers 
(Shinohara, Hiraki et al. 1998), head and neck cancers (Wong, Cheang et al. 
2008) and pancreatic cancer.   Conversely, increased DSG2 expression has 
been observed in skin cancers investigated by microarray (Brennan and 
Mahoney 2009).  
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Other desmosomal components exhibit altered expression in cancer.  
Plakophilin 1 expression is lost in oesophageal squamous cell carcinoma 
(Sobolik-Delmaire, Katafiasz et al., 2007) and plakophilin 3 loss has been 
demonstrated in colorectal cancer (Aigner, Descovich et al. 2007).  Reduced 
expression of desmoplakin has been correlated with the progression of a 
variety of cancers including breast cancer (Davies, Gee et al. 1999).    
 
Plakoglobin appears to have both oncogenic and tumour suppressor effects. 
As described in section 1.4.3, plakoglobin may have a role in the wnt 
signalling pathway.  Overexpression of plakoglobin promotes cell proliferation, 
through the activation of c-myc (Kolligs, Kolligs et al. 2000) but also acts to 
inhibit apoptosis by induction of the pro-survival gene bcl-2 (Hakimelahi, 
Parker et al. 2000).  However, LOH at the plakoglobin gene locus on 
chromosome 17q has been identified in breast and ovarian tumours (Aberle, 
Bierkamp et al. 1995) and restoration of plakoglobin in bladder cancer cell 
lines was able to reduce proliferation and migration (Rieger-Christ, Ng et al. 
2005).  This and other evidence indicates that plakoglobin plays an important 
role in cancer, although this may be related more to its signalling capacity 
than its structural role.  It has been suggested that sequestration of 
plakoglobin in desmosomes may serve to regulate the non-junctional pool of 
plakoglobin available for signalling (Chidgey and Dawson 2007). 
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The epithelial-mesenchymal transition (EMT) in cancer allows epithelial cells 
to gain mesenchymal characteristics i.e increased motility and invasiveness. 
In order for this to take place, intercellular adhesion is downregulated.  
Dissociation of both adherens junctions and desmosomes is central feature of 
EMT.  The EMT regulators Slug, Snail and zinc finger binding proteins ZEB1 
and ZEB2 have been shown to cause desmosomes to dissociate (Savagner, 
Yamada et al. 1997; Vandewalle, Comijn et al. 2005).  In keeping with the role 
of EMT in normal cell differentiation and repair, wounding of the epithelium 
results in Slug-mediated desmosome-dissociation, which allows desmosomes 
to migrate from the wound edges to fill the defect (Savagner, Kusewitt et al. 
2005). 
 
Desmosomal proteins have also been shown to be targeted in apoptosis 
(Weiske, Schoeneberg et al. 2001).  Also, DSC3 has been shown to be a p53 
target gene in breast cancer (Oshiro, Watts et al. 2003).  More recently the 
desmosomal related protein PERP has also been implicated in cancer.  It is 
activated by p53 and p63 to mediate their tumour suppressor function in skin 
squamous cell carcinoma (Dusek and Attardi 2011), although the role of 
PERP in desmosomes has not been fully elucidated. 
 
A potential role for desmosomes in cell proliferation and cancer has emerged 
from transgenic mouse studies.  This misexpression of the desmogleins 
DSG2 and DSG3 in inappropriate layers of the epidermis results in a hyper-
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proliferative phenotype that resists apoptosis (Merritt, Berika et al. 2002; 
Brennan, Hu et al. 2007). Similarly misexpression of desmocollin 3 in the 
epidermis results in altered differentiation (Hardman, Liu et al. 2005).  DSG2 
misexpression activates multiple signalling pathways, including PI-3K/AKT, 
mitogen-activated protein kinase (MAPK) and NF-ΚB pathways (Hardman, Liu 
et al. 2005; Brennan, Hu et al. 2007) whereas misexpression of DSC3 
increases β-catenin transcriptional activity (Hardman, Liu et al. 2005).  
Furthermore, deletion of the desmoplakin gene in a pancreatic cancer mouse 
model results in increased invasive potential (Chun and Hanahan 2010). 
 A role for desmosomes in cancer has been inferred from experiments in 
cultured cells.  For example, transfection of desmosomal proteins into non-
adhesive fibroblasts was able to inhibit the invasive behaviour of the cells 
(Tselepis, Chidgey et al. 1998).  By contrast, knockdown of DSC2 in colonic 
adenocarcinoma-derived cells promotes cell proliferation and transformation   
through activation of the AKT/β-catenin signalling (Kolegraff, Nava et al. 
2011).   
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1.5 Aims 
To determine the role of desmosomal cadherins in colorectal cancer, three 
lines of investigation were pursued: 
 
1. The role of the desmocollins in colorectal cancer was investigated by 
measuring their expression levels in a series of matched normal and 
tumour samples by western blotting and real-time polymerase chain 
reaction (PCR).  As part of this study, desmoglein mRNA levels in the 
matched normal and tumour samples were also measured by real time 
rt-PCR. 
 
2.  A cell culture model was established to determine the role of 
desmosomal cadherins in cell behaviour.  In these experiments 
antisense cDNAs were used to knockdown desmocollin 2 and 
desmoglein 2 mRNA levels in cultured LS174T colon cancer cells. 
 
 
 
3. Little is known of how desmosomal cadherin gene expression is 
regulated in the colon.  Thus, reporter gene assays were carried out in 
cultured Caco2 colon cancer cells to identify transcription factors that 
are important in the regulation of desmocollin 2 and desmoglein 2 gene 
expression in colonic epithelial cells. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
 
2.1 Human tissue samples 
Specimens were collected from patients undergoing surgery for colorectal 
cancer at the Queen Elizabeth Hospital, Birmingham with appropriate consent 
and in accordance with local ethics committee guidelines.  Matched samples 
of colorectal cancer and normal colonic tissue (from macroscopically normal 
tissue within the surgical specimen) were harvested and immediately frozen 
and stored in liquid nitrogen at -80°C (Table 2.1).  Samples were used from 21 
patients, of which 13 were male and 8 female.  The median age was 76 years 
(interquartile range 62-80 years).   
 
In addition, tissue was obtained from patients undergoing surgery for non-
neoplastic conditions to provide control samples.  Normal Control patient 1 
(NC1) underwent a total colectomy for distal ulcerative colitis limited to the 
recto-sigmoid and refractory to medical treatment.  Specimens were taken 
from the caecum, as far away from the involved tissue as possible.  Normal 
Control patient 2 (NC2) underwent an anterior resection of the rectum for 
diverticular disease with covering ileostomy formation.  The excised disc of 
skin from the ileostomy site provided a normal skin control.  Both samples 
were taken with the appropriate consent and were stored in liquid nitrogen at  
-80°C. 
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Table 2.1 Clinicopathological features of tumour samples 
   
Number of patients 
 
Dukes Stage 
 
A 
 
1 
 B 13 
 C 5 
 D 2 
   
T Stage 1 1 
 2 0 
 3 12 
 4 8 
   
Location Right 10 
 Transverse 2 
 Sigmoid 4 
 Rectum 5 
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2.2 Cell lines 
The following cell lines were obtained from the American Type Culture 
Collection (ATCC):  
LS174T is a colon adenocarcinoma cell line derived from 58 year old 
Caucasian female with a Dukes B adenocarcinoma (Tom, Rutzky et al. 1976). 
 
Caco2 is a colonic adenocarcinoma cell line derived from a 72 year old 
Caucasian male patient (Fogh, Fogh et al. 1977).   
 
HT29 is a colonic adenocarcinoma cell line, originally isolated from a 44 year 
old female patient (Fogh, Fogh et al. 1977). 
 
MCF7 is a human breast adenocarcinoma cell line, derived from the pleural 
effusion of a 69 year old Caucasian female patient (Soule, Vazguez et al. 
1973).  
 
Primary Normal Human Epithelial Keratinocytes (NHEK-A cells) were 
obtained from TCS Cellworks. 
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2.3 Tissue culture 
LS174T cells were cultured in Dulbecco’s Modified Essential Medium (DMEM) 
(Sigma) supplemented with 10% foetal bovine serum (Sigma), 1% non-
essential amino acids (Invitrogen), 2mM L-Glutamine (Sigma) and 5μl/ml 
bovine insulin (Sigma).   
 
Caco2 and MCF7 cells were cultured in Eagle’s Minimum Essential Modified 
Medium (EMEM, Sigma), supplemented with 20% foetal bovine serum, 1% 
non-essential amino acids, 1% L-Glutamine and 5μl/ml bovine insulin.   
 
HT29 cells were cultured and maintained in RPMI medium (Sigma), 
supplemented with 10% foetal bovine serum and 1% L-Glutamine. 
 
Primary Normal Human Epithelial Keratinocytes (NHEK-A cells) were cultured 
in Keratinocyte Growth Medium (KGM) (TCS Cellworks).  All cells were 
maintained at 37ºC in 5% CO2. 
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2.4 RNA and protein extraction 
Tumour and normal colonic mucosa specimens were cut into 5mm x 10mm 
pieces and homogenised in 0.75ml of TRI Reagent (Helena Biosciences).  
RNA and protein was prepared according to the manufacturer’s protocol.  
RNA concentration was determined by the measurement of absorbance at 
260nm in a spectrophotometer.  Protein concentration was measured using 
the Bio-Rad Protein Assay (Bio-Rad) according to the manufacturer’s 
instructions with Bovine Serum Albumin (BSA) as standard.  
 
To prepare RNA from human skin 10mm2 pieces of skin were first chopped 
with a scalpel whilst frozen, into smaller (1mm2) pieces.  These were added to 
2ml of guanidinium thiocyanate (GTC) buffer (Sambrook, Fritsch et al. 1989).  
200μl 2M sodium acetate (pH 4.0), 2ml water saturated phenol and 400μl 
chloroform was added and the mixture vortexed for 10sec, incubated on ice 
for 10min, and centrifuged for 20min at 10,000rpm and 4°C.  The upper 
aqueous layer was then added to 2ml isopropanol and stored at -20°C for >1 
hour.  The sample was centrifuged (20min at 10,000rpm and 4°C) and the 
pellet dissolved in 400μl nuclease free water.  20μl 3M sodium acetate (pH 
6.0) and 1ml ice-cold ethanol were added and the sample stored at -70°C for 
>1h.  The sample was then centrifuged for 20min at 13,000rpm and 4°C.  The 
pellet was washed with 70% ethanol, dried and dissolved in 50μl nuclease 
free water.  RNA concentration was determined by the measurement of 
absorbance at 260nm in a spectrophotometer. RNA quality was checked by 
denaturing formaldehyde polyacrylamide gel electrophoresis (section 2.5.3). 
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RNA was extracted from cultured cells using RNA-Bee (Biogenesis)   Cells 
were grown to 70% confluence and washed in phosphate buffered saline.  For 
each 100mm plate, 2ml of reagent was used to lyse the cells.  Chloroform 
(0.25ml) was added and the mixture vortexed and incubated on ice for 5 min.  
Samples were then centrifuged for 15min at 1,000 rpm and 4°C.  RNA was 
precipitated by mixing the upper aqueous phase with an equal volume of 
isopropanol, followed by incubation at room temperature for 10 min and 
centrifugation at 10,000rpm for 10 min at 4°C.  The RNA pellet was washed in 
70% ethanol and allowed to dry.  RNA was dissolved in 50μl nuclease-free 
water. 
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2.5 Analysis of RNA 
 
2.5.1 Quantitative reverse-transcriptase mediated real time PCR 
Reverse transcription was performed using the First Strand cDNA Synthesis 
kit (Roche) with 1μg of RNA per reaction to yield 20μl cDNA.  Real-time PCR 
primers (Table 2.2) were designed using Primer Express software, version 1.5 
(PE Applied Biosystems, Cambridge, UK) and obtained from Alta Biosciences 
(University of Birmingham, Birmingham, UK).  Real-time PCR was performed 
using the SYBR Green method in the ABI Prism® 7700 Sequence Detector.  
The Sensimix (dT) kit (Quantace) was used together with primers at 300nM 
concentration and 1μl of cDNA in each 25μl reaction. An epithelial cell specific 
gene, cytokeratin 8 (CK-8) was used as an internal control.  Thermal cycling 
conditions were as follows:  50°C for 2min, 95°C for 10min, then 40 cycles of 
95°C for 15sec and 60°C for 1min.  All samples were run in triplicate, together 
with positive and negative controls.  Interpretation was performed using the 
comparative threshold (CT) method with ABI Sequence Detection System 
software and Microsoft Excel. 
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Table 2.2 Primers used for real-time PCR 
 
Gene  
 
Accession 
number 
 
Sequence of Forward (F) and Reverse 
(R) primers 
 
Size of PCR 
product (bp) 
 
DSC1 
 
NM_024421 F: TGCCAAACACTCCTCACTCAAA 
R: TTCAATGGCTTGACAACACACA 
124 
DSC2 
 
NM_024422 F: CGGAGATTGTTGCGGTTGA 
R: GGAAAGACGTGCTGCTGTATCA 
134 
DSC3 
 
NM_001941 F: GGCTGTTGCGCTGTCTGATAA 
R: GCCCAAGGAATTCTCTTGCA 
202 
DSG1 
 
NM_001942 F: CGGAAACGGAGCCAAAGATT 
R: TCAAAGCCAGCTGCACTACGA 
156 
DSG2 
 
NM_001943 F: AAACAGTGGCCCTTTCAGTTTC 
R: GTTGCAGCAGCACACTGGTACT 
101 
DSG3 
 
NM_001944 F: GTCTCCTGCTGCTGCTGTTG 
R: TCCTTCTGAGCCATCAGGAACT 
113 
DSG4 
 
AY227350 F: GCAAGGAAGAGGAGCTCTACCA 
R: GCATACGCTTTCTCCGAGAAGT 
101 
CK-8 
 
NM_002273 F: GATCGCCACCTACAGGAAGCT 
R: ACTCATGTTCTGCATCCCAGACT 
70 
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2.5.2 Semi-quantitative reverse transcriptase-mediated PCR  
RNA was extracted from cultured cell lines and cDNA synthesised as 
described (section 2.5.1).  Semi-quantitative PCR was performed using the 
Expand High Fidelity PCR System (Roche) and the following thermal cycling 
conditions:  94°C for 5min, followed by 25 cycles of 94°C for 30seconds, 57°C 
for 30 seconds and 72°C for 2min.  The primers shown in Table 2.3 were 
used to amplify desmocollin and desmoglein DNA.    
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Table 2.3  Primers used for semi-quantitative RT-PCR 
Gene Sequence of Forward (F) and Reverse (R) 
primers 
Size of PCR 
Product (bp) 
 
DSC1 F: TTGGATACACACTGGACC 
R: CCAGAAAGAATTGAAAAGGTGG 
400 
DSC2 F: AGAAGCCTGGATAGAGAGG 
R: CCAAGGATTGGCGGTGGA 
460 
DSC3 F: GCACTCCTGCAGCCCAAT 
R: TACTCATCCAACTCAGTGTC 
600 
DSG1 F: GACCTGCTAGCTGTTGATTC 
R: GCTGGTATCATAGTTAGTGG 
240 
DSG2 F: CCATCACTGGCACAGTCCT 
R: AGGAGTCATGCTGTGCTTC 
360 
DSG3 F: CAATCACAGCTGAGGTTCTG 
R: CAGTGTCAAGCTGCGTGG 
350 
DSG4 F: GGCATCTACACAGAGGACAT 
R: GTTGATGTCTGCGTCAGCGT  
522 
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2.5.3 Formaldehyde agarose gel electrophoresis  
Formaldehyde agarose gel electrophoresis was performed according to the 
method of Sambrook, Fritsch et al (1989).  RNA was precipitated using lithium 
chloride, resuspended in RNA sample buffer and incubated at 55ºC in a heat 
block for 30min.  The samples were then cooled on ice for 10min prior to 
adding 3µl of formaldehyde gel-loading buffer (Sambrook, Fritsch et al. 1989) 
with ethidium bromide (1mg/ml).  Samples were loaded on formaldehyde 
denaturing agarose gels alongside a High Range RNA ladder (Fermentas) 
and run at 50V for 2 hours (to check RNA quality) or 4 hours (for northern 
blotting).  2µg of RNA was used when checking RNA quality, whereas 10-
20µg of RNA per lane was used for northern blotting.  RNA was visualised 
using a transilluminator and UV light. 
 
2.5.4 Northern blotting 
RNA was resolved by denaturing formaldehyde gel electrophoresis as 
described (section 2.5.3).  The gel was washed twice in 10x SSC buffer 
(Sambrook, Fritsch et al. 1989) for 30min with agitation.  Samples were 
transferred onto Amersham Hybond™-N (GE Healthcare) using 10x SSC 
buffer.  The membrane was then washed in 2x SSC buffer, dried and baked at 
80ºC for 2 hours to facilitate crosslinking of the RNA to the membrane.  This 
was then placed in a hybridisation bottle with 10ml of hybridisation buffer and 
incubated at 42ºC for 30min.  The hybridisation probe was denatured by 
heating to 95ºC for 5min then added to the hybridisation bottle and incubated 
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at 42ºC for at least 4 hours.  The filters were then removed, washed and 
exposed to X-ray film at -80ºC.  The X-ray film was developed after 4 days. 
 
2.5.5 Northern blot hybridisation probes 
2µg of DNA (made up to 10µl with water) was heated to 95ºC for 3min and 
then cooled on ice for 10min.  Labelling of the probe DNA was achieved using  
the Radiolabelling Primer Kit (Roche), with 2µl Solution 6, 1µl of each of 
dATP, dTTP and dGTP, 4µl [α-32P]-dCTP (3000Ci/mmol) (ICN Biomedical 
Research Products) and 1µl of Klenow enzyme.  The mixture was incubated 
at 37ºC for 45min.  Unincorporated nucleotides were removed using the 
QIAquick Nucleotide Removal Kit (Qiagen).   The labelled probe was stored at 
-80ºC in a lead-lined box until needed.   
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2.6 Western blot analysis 
Protein samples (10μg) was denatured by adding 6M urea and 5μl of 2x 
sample buffer (Sambrook, Fritsch et al., 1989) (to a total volume of 10μl) and 
incubating at 95°C for 5min.  Proteins were resolved by SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE) using standard techniques (Sambrook, 
Fritsch et al., 1989).  Proteins were transferred onto polyvinylidene difluoride 
(PVDF) membrane (Hybond P, Amersham Biosciences).  Blots were blocked 
in 5% non-fat dried milk in Tris-buffered saline (TBS) containing 0.1% Tween 
(TTBS).  Blots were probed with primary antibodies (Table 2.4), followed by 
either horseradish peroxidase (HRP) conjugated anti-rabbit IgG (1:10,000, 
Sigma) or HRP-conjugated anti-mouse IgG (1:1000, Jackson 
Immunoresearch) secondary antibodies (as appropriate).  Proteins were 
visualised with an enhanced chemiluminescence (ECL) substrate (Amersham; 
as specified by the manufacturer) and autoluminography.   
 
In order to obtain a quantitative analysis, the western blots were assessed 
using Image J software (v.1.33, National Institute of Health, USA 
http://rsbweb.nih.gov/ij) which allowed comparison of the protein content 
between normal and tumour samples after normalisation with cytokeratin 8. 
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Table 2.4 Primary antibodies used for western blotting 
Protein           Antibody Dilution 
DSC1  JCMC, (North, Chidgey et al. 1996) 1:10,000 
DSC2  610120, Progen 1:1000 
DSC3  U114, Progen 1:50 
DSG2  33-3D, (Vilela, Hashimoto et al. 1995) 1:50 
Cytokeratin 8  C51, Zymed 1:200 
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2.7 Plasmids 
2.7.1 pBATEM2 vector 
The eukaryotic expression vector pBATEM2 (Fig 2.1) was provided by M 
Takeichi, Kyoto University, Japan.  It is based on the plasmid pBR322 and 
contains DNA encoding mouse E-cadherin downstream of a composite 
promoter consisting of chicken β-actin and herpes simplex virus thymidine 
kinase DNA, and upstream of simian virus 40 polyadenylation signals (Nose, 
Nagafuchi et al. 1988).  Human DSC2 and DSG2 antisense cDNA was cloned 
into the BglII and HindIII sites of pBATEM2 and the resulting plasmids used to 
stably transfect LS174T cells (see Chapter 4).  As pBATEM2 does not contain 
a selectable marker, LS174T cells were co-transfected with pBATneo (also 
provided by Dr Takeichi), which confers resistance to the antibiotic G418. 
 
Fig 2.1 pBATEM2.   
 
 
TK, thymidine kinase promoter; SVter , simian virus 40 polyadenylation signal.  
In pBATneo the E-cadherin cDNA is replaced by the neo gene, encoding 
resistance to G418.  
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2.7.2 pGL2 and pGL3 reporter vectors 
Luciferase reporter vectors pGL3-Basic and pGL3-Enhancer (Fig 2.2) were 
obtained from Promega.  pGL3-Basic contains a firefly luciferase reporter 
gene (luc) downstream of a multiple cloning site (MCS).  It lacks enhancer 
elements and is suitable for the analysis of strong promoters.  pGL2-Enhancer 
also contains luc downstream of a MCS.  It contains an SV40 enhancer and 
so is suitable for analysing weaker promoter elements.  Fragments of the 
human DSC2 and DSG2 promoters were inserted into the KpnI and XhoI sites 
of pGL2-Basic and pGL2-Enhancer reporter plasmids and used in transient 
transfection of Caco2 cells (see Chapter 5).   
 
Plasmids pGL2E-Dsc1(0.4) and pGL3B-Dsc3(0.3) were provided by Dr MA 
Chidgey (University of Birmingham).  Plasmid pGL2E-Dsc1(0.4) contains 
bases -1 to -417 of the mouse Dsc1 promoter in pGL2-Enhancer and plasmid 
pGL3B-Dsc3(0.3) contains bases -1 to -293 of the mouse Dsc3 promoter in 
pGL3-Basic (Smith, Zhu et al. 2004). 
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Fig 2.2 pGL3-Basic and pGL2-Enhancer plasmids.   
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2.7.3 pRL-TK 
Vector pRL-TK (Promega) (Fig 2.3) was used to monitor transfection 
efficiency in luciferase reporter assays.  It contains the herpes simplex virus 
thymidine kinase (HSV-TK) promoter upstream of a gene encoding Renilla 
luciferase. 
 
 
Fig 2.3 pRL-TK. 
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2.7.4 pcDNA3 based plasmids 
The eukaryotic expression vector pcDNA3 (Fig 2.4) was obtained from 
Invitrogen.  It contains a multiple cloning site downstream of the 
cytomegalovirus (CMV) promoter and upstream of Bovine Growth Hormone 
(BGH) polyadenylation signal.   pcDNA3 based plasmids encoding a variety of 
transcription factors were co-transfected into Caco2 cells with pGL3-Basic 
reporter constructs (see Chapter 5).  pcDNA3 plasmids encoding full-length 
rat C/EBPα and C/EBPβ were provided by Dr RC Smart of North Carolina 
State University.  pcDNA3 plasmids encoding  mouse C/EBPδ, C/EBPζ, c-fos, 
c-jun, JunB, AP2α, AP2γ, AP4 and p53 were provided by Dr MA Chidgey.  
Plasmids encoding full-length human plakoglobin and Lef1 were also provided 
by Dr Chidgey.  A pcDNA3 plasmid encoding a stable S37A mutant version of 
full-length human β-catenin, which is resistant to degradation, was provided 
by Dr SW Byers of Georgetown University.   
Fig2.4 pcDNA3 
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2.8 DNA manipulation 
 
2.8.1 Restriction enzyme digests 
Restriction enzyme digests were performed using enzymes from a variety of 
sources according to the manufacturer’s instructions.  Usually digests 
contained 1μl restriction enzyme (10 units), 1μl of the appropriate buffer (10x), 
1μl BSA, 5μl of DNA and water (in a total volume of 10μl).  Digests were 
incubated for 1h at 37ºC. 
 
2.8.2 Agarose gel electrophoresis 
Agarose gels were prepared and run according to the method of Sambrook, 
Fritsch et al. (1989), using 1% agarose (Sigma) dissolved in 1 x TAE buffer 
(40mM-Tris acetate, 1mM-EDTA, pH7.8).  DNA samples were resolved 
alongside λHindIII markers (Roche).  Gels were stained by soaking in 
ethidium bromide solution (5μg/ml) for 10-20min and DNA was visualised on a 
UV transilluminator.  
 
2.8.3 DNA isolation by electroelution 
DNA samples were resolved by agarose gel electrophoresis.  The agarose  
containing the required DNA was excised from the gel under UV light and  
placed in dialysis tubing (Medicell International Ltd) with 1x TAE buffer.  The 
ends of the tubing were clamped, the tubing placed in an electrophoresis tank 
and a current of 90V applied for 45min.  The current was reversed for 30sec 
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and the liquid aspirated from the dialysis tubing.  The sample was extracted 
with phenol and chloroform and the DNA recovered by ethanol precipitation. 
2.8.4 Ethanol precipitation of DNA 
DNA was precipitated using one half-volume of 8M-ammonium acetate and 2 
volumes ethanol.  After vortexing, the sample was placed at -80ºC for >30 
min, and then centrifuged at 13,000rpm for 10min.  The DNA pellet was 
washed with 70% ethanol, dried and redissolved in the required volume of TE 
buffer (10mM Tris.HCl, 1mM-EDTA, pH8.0). 
 
2.8.5 Ligation reactions 
DNA fragments were ligated using T4 DNA ligase (200 units) and ligase buffer 
(both from New England Biolabs) in a 10μl reaction.  Ligation reactions were 
carried out at room temperature for 16h.    
 
2.8.6 Transformation of competent bacteria with DNA 
Competent E.Coli XL1-Blue cells were prepared using standard techniques 
(Sambrook, Fritsch et al., 1989).  DNA was transformed into these cells using 
the heat shock method of Sambrook, Fritsch et al (1989).  Briefly, the host 
cells were thawed in a 37ºC water bath and allowed to rest on ice for 5min.  
Plasmid DNA was added, the cells left on ice for a further 30 minutes and 
then heat shocked (42ºC for 2min).  1ml of LB medium (Sambrook, Fritsch et 
al., 1989) (without ampicillin) was added and the cells incubated at 37ºC for 
1h.  Cells were pelleted by low speed centrifugation, resuspended in 100µl of 
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LB medium, spread on LB/agar plates (1% agar in LM medium with 50µg/ml 
ampicillin) and incubated overnight at 37ºC. 
 
2.8.7 Plasmid DNA isolation 
For small scale Mini-Prep DNA isolation, single colonies were picked from 
plates and incubated in 5ml LB medium (with 50µg/ml ampicillin) at 37ºC, 
overnight in a shaking incubator.  Plasmid DNA was extracted from 1.5ml of 
each culture using the alkaline lysis method (Sambrook 1989).  For larger 
scale Midi-Prep DNA isolation 1ml of an overnight culture (as above) was 
added to 100ml of fresh LB medium (with 50µg/ml ampicillin) and incubated at 
37ºC overnight (with agitation).  The Qiagen Plasmid Midi Kit was used to 
prepare the DNA from these cultures according to manufacturer’s protocol.  
The recovered DNA was dissolved in 100µl TE buffer.  DNA concentration 
was measured by spectrophotometry at 260nm. 
 
2.8.8 DNA sequencing 
The BigDye Terminator® v3 cycle sequencing kit (Applied Biosystems) was 
used with 500ng of DNA and 3pmol of primer per reaction. Thermal cycling 
conditions were as follows: 96ºC for 3min, then 25 cycles of 96ºC for 10sec, 
50ºC for 5 sec, and 60ºC for 4min.  Reaction products were precipitated using 
2.5µl 0.2M EDTA and 64µl ethanol and recovered by centrifugation at 
13000rpm for 10min.  The pellet was washed with 70% ethanol (250µl), dried 
and dissolved in Hi-Di Formamide (Applied Biosystems).  Samples were 
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analysed on ABI PRISM® DNA Analyser (Applied Biosystems) in the 
Functional Genomics Laboratory, University of Birmingham.  Data were 
analysed using Chromas 1.45 sequence analysis software and the BLAST 
tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
 
2.9 Cloning of DSC2 and DSG2 antisense DNA 
To produce DSC2 antisense constructs for knockdown experiments (Chapter 
4) fragments of DSC2 cDNA, 824 and 785bp in length, were obtained by 
restriction enzyme digestion of a full length human DSC2 cDNA clone 
(provided by T Magee, Imperial College, London).  These were cloned into the 
pBAT backbone, derived from pBATEM2 (section 2.7.1).  The procedures 
used are described in detail in Chapter 4.  To produce DSG2 antisense 
constructs fragments of DSG2 cDNA were amplified by RT-PCR (section 
2.5.2) using RNA isolated from human skin as starting material.  The primers 
used are given in Table 2.4 were used.  Fragments of DSG2 cDNA, 825 and 
811bp in length, were amplified using this procedure and cloned into the T-
vector pDK101 (Kovalic, Kwak et al. 1991), sequenced to ensure that no 
unexpected mutations had been introduced during PCR amplification and 
released by restriction enzyme digestion.  Again, the fragments were cloned 
in the antisense orientation into the pBAT backbone using the procedures 
described in chapter 4. 
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Table 2.5.  Primers used to amplify the DSG2 antisense fragments 
 
PCR fragment Sequence of Forward (F) and Reverse (R) primers 
 
DSG2AS1 F: AAGTCGACCTTGCAGAAGAAAGAGGACTC 
         Sal1 
R: TTGGATCCACTGAAGTCAAGATTCTTCAT 
          BamH1 
 
DSG2AS2 F: AAGTCGACGAAGCACAGCATGACTCCTA 
          Sal1 
R: TTGGATCCAGAGTGAATGTGAAGCTGT 
            BamH1 
 
 
Restriction enzyme sites used for cloning are underlined.   
 
2.10 Cloning of the human DSC2 and DSG2 promoters 
Yeast artificial chromosome (YAC) clones 14E-B5 and 9G-C3, containing 
DSC2 and DSG2 promoter DNA respectively, were obtained from MRC 
geneservice.  Clones were streaked out on LB/agar plates, containing 
ampicillin (50μg/ml) and tetracycline (12.5μg/ml), and single colonies picked 
and expanded.  YAC DNA was isolated using the supplier’s instructions.   
Two fragments of the human DSC2 promoter, bases -1 to -999 and -1 to -563, 
were amplified by PCR using the oligonucleotides in table 2.6.  Similar sized 
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fragments of the human DSG2 promoter were amplified using the same 
methodology.  50ng of YAC DNA was used per reaction. The Expand High 
Fidelity PCR System (Roche) was used with the following thermal cycling 
conditions:  94°C for 5min, followed by 25 cycles of 94°C for 30sec, 57°C for 
30sec and 72°C for 2min. 
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Table 2.6 Primers used to isolate DSC2 and DSG2 promoter fragments.   
 
Promoter 
fragment 
 
Sequence of Forward (F) and Reverse (R) primers 
DSC2  
-1 to -999 
F: AAGGTACCGAACTCTCCACTGGATGTTCA 
             KpnI    
R: AAGAGCTCCCTCTCCCGAGCCCCGTCCAG 
            XhoI                                                  
 
DSC2 
-1 to -563 
F: AAGGTACCGGCTCAGACCTCGCTCTGTAA 
             KpnI   
 R: AAGAGCTCCCTCTCCCGAGCCCCGTCGAC 
             XhoI                                                 
 
DSG2 
-1 to -1061    
F’:AAGGTACCTGAACCCTTAAGTTCTAGACACTGC 
             KpnI    
R’: AAGAGCTCGCGTGGGAGCGGAGGCGGAGG 
             XhoI                                                
 
DSG2  
-1 to -501 
F’: AAGGTACCTTGGTCCCGCAGGACTCTGCT 
            KpnI 
R’: AAGAGCTCGCGTGGGAGCGGAGGCGGA 
            XhoI                                                   
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2.11 Transfection of cultured mammalian cells 
2.11.1 Stable transfection of antisense plasmids into LS174T cells 
To obtain stable LS174T transfectants expressing antisense cDNA (Chapter 
4), pBAT plasmids (section 2.7.1) containing either DSC2 or DSG2 antisense 
cDNA (100μg) were co-transfected into the cells with the vector pBATneo 
(10μg).  Control cells were transfected with pBATneo alone.  LS174T cells 
were plated onto 9cm tissue culture dishes and grown until 70% confluent.  
The cells were rinsed with phosphate buffered saline and DNA added in the 
form of a calcium phosphate precipitate using standard methodologies 
(Sambrook, Fritsch et al. 1989).  The precipitate was allowed to settle on the 
cells for 20min and growth medium (section 2.3) added.  After 48h the growth 
medium was supplemented with 800μg/ml G418 (Sigma).  Surviving cell 
clones were picked after 2-3 weeks, expanded and screened by northern 
blotting, real-time PCR and western blotting (Chapter 4).   
 
2.11.2 Transient transfection of luciferase reporter plasmids into Caco2 
cells 
Caco2 cells were grown to 70% confluence in 24 well plates in normal growth 
medium (section 2.3).  Transient transfections were performed in serum free 
EMEM medium using Lipofectamine reagent (Invitrogen) as described by the 
manufacturer.  In standard DSC2 and DSG2 reporter assays, 500ng of 
reporter plasmid was added per well, and transfection efficiency was 
monitored using plasmid pRL-TK (50ng).  Cells were incubated in the 
transfection mixture for 4h in 5% CO2 at 37ºC.  The transfection mixture was 
then aspirated from the cells and replaced with normal growth medium and 
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cells incubated for a further 48h.  After 48h growth medium was removed and 
cells lysed using Passive Lysis Buffer (Promega).  Lysates were stored at -
700C.  Each experiment was performed in triplicate on at least two occasions 
to demonstrate reproducibility.       
 
To determine the effect of transcription factors on transcriptional activity 
reporter plasmids were co-transfected with pcDNA3 constructs (section 2.7.4).  
In these experiments it was not possible to include the pRL-TK plasmid in the 
co-transfection experiments as the Renilla luciferase activity has previously 
been noted to be adversely affected by pcDNA3-based plasmids (Smith, Zhu 
et al. 2004). This ‘promoter crosstalk’ has been attributed to trans effects 
between promoters on cotransfected plasmids (Farr and Roman 1992).  In 
these experiments variability in transfection efficiency between plates was 
mitigated by including control transfections with the empty vector on each 
plate, and results expressed as mean activity relative to that of the empty 
vector (± standard deviations).     
 
2.12 Measurement of luciferase activity 
Lysates from transfection experiments were thawed, centrifuged at 13,000 
rpm for 3min and the supernatant removed.  Firefly and Renilla luciferase 
activity in lysates was measured using the Dual-Luciferase™ Reporter Assay 
System (Promega).  Luminescence was measured in a Wallac Victor 2 1420 
Multilabel luminometer (Perkin-Elmer).   
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2.13 Statistics  
Results were analysed using GraphPad Prism v5 (GraphPad Software, 
California, USA).  Statistical significance was determined using an unpaired t-
test (p<0.05 indicated by *). 
 
 
 
  
67 
 
CHAPTER 3  
DESMOSOMAL CADHERIN EXPRESSION IN COLORECTAL CANCER 
 
3.1 Introduction 
Although desmosomes are found in all epithelial tissues, their expression 
patterns vary.  Desmocollin 2 (DSC2) and desmoglein 2 (DSG2) are common 
to all desmosome-forming tissues and in simple epithelia, such as the colonic 
mucosa, these are the only desmosomal cadherins expressed (Nuber, 
Schafer et al. 1995).  They are constitutive components of desmosomes and 
both are necessary for normal desmosome function (Tselepis, Chidgey et al. 
1998).  Loss of either DSC2 or DSG2 in a tissue expressing only these 
desmosomal cadherins would be expected to result in altered desmosomal 
adhesion.   
 
As part of a concurrent study, immunohistochemical analysis of a series of 
colorectal tumours demonstrated alterations in the patterns of desmosomal 
cadherin expression.  Sixteen tumours were examined, of which 8 showed a 
reduction in DSC2 expression, as well as a re-localisation of the protein from 
the membrane to the cytoplasm.  In addition, all 16 specimens were found to 
exhibit de novo expression of DSC1 protein and 7/16 exhibited de novo DSC3 
protein expression. 
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The initial aim of the experiments described in this chapter was to confirm 
these findings using western blotting.  Experiments were then carried out to 
determine whether changes in desmocollin expression were occurring at a 
transcriptional level using real-time RT-PCR.  Desmoglein expression was 
then examined at the mRNA level to determine whether changes in 
desmoglein expression patterns occur in colorectal cancer specimens. 
 
3.2 DSC2 protein expression in colorectal cancer 
Protein was extracted from matched specimens of histologically normal tissue 
and tumour material from 16 patients with colorectal cancer (described in 
Table 2.1).  The matched samples of normal and tumour protein were then 
examined by western blotting.  Tumour samples are often heterogeneous in 
nature with epithelial tissue contaminated by stromal tissue.  To ensure equal 
loading of epithelial tissue both DSC2 and cytokeratin 8 levels were measured 
in samples by western blotting.  On visual inspection of the western blots, it 
was apparent that DSC2 protein expression was reduced in 11/16 tumour 
samples (Fig 3.1).  Levels of DSC2 appeared to be unchanged in the 
remaining 5 samples.  Image J software was used to quantify the intensity of 
the bands on western blots.  This semi-quantitative analysis confirmed that 
the majority of tumours (14/16) showed a reduction in DSC2 protein 
expression whereas 2/16 exhibited increased DSC2 protein expression (Fig 
3.2).  A correlation of DSC2 expression levels with clinicopathological 
variables (patient age, tumour stage, tumour site) was sought.  However, due 
to the small numbers in each group, it was not possible to draw any 
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meaningful conclusions.  These results should therefore be viewed as an 
indicator to direct future investigations. 
The aim of the experiments described above was to compare DSC2 protein 
levels in histologically normal tissue with DSC2 protein levels in matched 
specimens of tumour material.  In addition, for completeness sake, the overall 
levels of DSC2 in the 16 normal samples were compared with overall levels of 
DSC2 in the 16 tumour specimens (after all of the samples had been 
normalised against the internal control, cytokeratin 8). This analysis showed 
the mean tumour DSC2 expression was significantly less (61.5%, p=0.0072) 
in the tumour samples than that in matched normal tissue (Fig 3.3).    
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Fig 3.1 DSC2 protein expression in matched normal and tumour samples 
 
 
 
 
Western blot showing examples of DSC2 and cytokeratin 8 (CK-8) expression 
in matched normal (N) and tumour (T) samples.  Note that the antibody used 
does not detect the smaller DSC2 ‘b’ protein.  CK-8, a cytoskeletal protein 
expressed in colonic cells, was used as a loading control.    
 
Fig 3.2  Semi-quantitative analysis of DSC2 protein expression in 
matched normal and tumour samples 
 
 
 
Image J software was used to quantify the intensity of protein bands on 
western blots. DSC2 protein expression was normalised to cytokeratin 8 and 
then compared in matched normal and tumour samples.  DSC2 protein 
expression was reduced (i.e. <1) in all but 2 of the tumours studied.  
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Fig 3.3 Overall levels of DSC2 protein in normal samples as compared to 
that in tumour samples   
 
 
Image J software was used to quantify the intensity of protein bands on 
western blots. DSC2 protein expression was normalised to cytokeratin 8 and 
the overall expression in the 16 normal samples was compared to the overall 
expression in the 16 tumour samples.  Overall expression in the normal 
samples was arbitarily set at 1.  The difference between the two sets of values 
was compared by unpaired t-test (p=0.0072). 
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3.3 DSC1 and DSC3 protein expression in colorectal cancer 
As part of the concurrent study de novo DSC1 and DSC3 expression was 
detected in colorectal tumours by immunohistochemistry.  Hence a series of 
western blots were performed to confirm these findings.  DSC1 and DSC3 
expression was measured in seven tumour samples and compared to that of 
normal colonic tissue taken from a patient undergoing surgery for a non-
cancerous condition.  As expected, no DSC1 or DSC3 protein was seen in the 
normal colonic tissue.  Protein bands of the correct molecular weight were 
identified in 4/7 tumour samples investigated for DSC1 protein and 3/7 for 
DSC3 protein (Fig 3.4).  Interestingly, expression of DSC1 and DSC3 was 
seen in samples where DSC2 protein expression was lost but also when it 
was maintained, suggesting that altered DSC2 expression is not necessarily 
the event that triggers expression of  DSC1 and DSC3 (Fig 3.5). 
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Fig 3.4 Western blots for DSC1 and DSC3 in colorectal tumour samples 
 
 
               
               
               
 
Western blots showing de novo DSC1 and DSC3 expression in colorectal 
cancer specimens. Lanes 1-7 contain tumour samples, lane 8 contains the 
negative control (normal colon) and lane 9 contains the positive control 
(protein extracted from NHEK cells).  Positive samples show 2 bands 
corresponding to the ‘a’ and/or ‘b’ isoforms. Note that NHEK cells express 
very low levels of CK-8. 
 
Fig 3.5 Western blots for tumour sample 20 
 
 
 
 
 
 
 
Western blots showing expression of all three desmocollin proteins in the 
same tumour sample.  De novo expression of DSC1 and DSC3 occurs even 
when levels of DSC2 protein are maintained. 
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3.4 DSC2 transcription in colorectal cancer 
 
Having determined that DSC2 protein expression is decreased in colorectal 
cancer, the next stage of the investigation was to identify possible 
mechanisms by which this occurs.  Specimens from 7 tumours with matched 
normal tissue were examined by real-time PCR to study DSC2 mRNA 
expression.  One sample showed increased DSC2 expression (a 32-fold 
increase).  However, the expression level in the majority (6/7) of samples was 
essentially unchanged (i.e. <2-fold change).  Hence the loss of DSC2 protein 
that is observed in tumour specimens by western blotting (Fig 3.1) does not 
appear to be due to a reduction of DSC2 mRNA.   
Again, for completeness sake, overall levels of DSC2 mRNA in the 7 normal 
samples were compared with those found in the 7 tumour samples (after all of 
the samples had been normalised against the internal control, cytokeratin 8).  
There was no significant difference between overall DSC2 mRNA levels in the 
normal tissue samples as compared to overall DSC2 mRNA levels in the 
tumour samples (Table 3.1). 
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Fig 3.6 Desmocollin mRNA expression patterns in matched specimens 
of histologically normal tissue and tumour material  
 
Desmocollin mRNA expression was measured in 7 matched pairs of normal 
and tumour samples by quantitative RT-PCR. 
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Table 3.1 Desmocollin real-time PCR data 
 
 
 
Normal Tumour P value 
unpaired t test 
 
DSC2 
 
19.32  (± 3.59) 
 
18.49 (±2.43) 
 
CK-8 17.95  (± 1.82) 18.04 (± 1.4)  
ΔCt 1.36      (±2.86) 0.46   (±1.77) 0.49 
    
DSC1 29.58  (± 2.28) 28.1 (±1.6)  
CK-8 18.07    (± 1.56) 18.23 (± 1.72)  
ΔCt 11.5 (±3.3) 9.89     (±1.73) 0.26 
    
DSC3 29.01  (± 5.7) 27.3 (±4.6)  
CK-8 18.56(± 3.01) 18.4 (± 2.5)  
ΔCt 10.5  (±5.83) 8.9 (±5.5) 0.32 
    
 
Table shows mean Ct values (± standard deviation) for 7 normal controls and 
the 7 tumour specimens for DSC1, DSC2 and DSC3.  Mean Ct values were 
also determined for internal control CK-8 and subtracted from the mean Ct 
values for each DSC under investigation to give ΔCt value. The ΔCt value for 
normal and tumour samples was compared by t-test.   
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3.5 DSC1 and DSC3 transcription in colorectal cancer 
Having detected the DSC1 and DSC3 protein by immunochemistry and 
western blotting, further evidence to support this observation was sought by 
investigating DSC1 and DSC3 mRNA expression. Seven matched samples 
were evaluated for DSC1 expression by real-time PCR (Fig 3.6).  DSC1 
mRNA expression was upregulated in 3/7 tumour samples and unchanged in 
the remaining four samples (i.e. there was a less than 2-fold difference 
between the normal and tumour tissue).  A correlation was found between 
DSC1 message levels and protein expression.  For example, the sample with 
the maximum increase at the mRNA level also expressed high levels of DSC1 
protein.  No DSC1 protein was detected in samples with <2-fold increase in 
DSC1 transcript.  
 
Matched samples from seven colorectal cancer patients were investigated for 
DSC3 mRNA expression (Fig 3.6).  DSC3 mRNA expression was upregulated 
in 4/7 tumour samples and unchanged in the remaining three when compared 
to the matched normal tissue.  Samples containing upregulated DSC3 
transcript also contained DSC3 protein by western blotting.  No DSC3 protein 
was found without a corresponding increase in mRNA levels.   
 
Although it is clear that de novo DSC1 and DSC3 expression occurs in some 
tumour samples, both at the protein and mRNA levels, there was no 
statistically significant difference between overall DSC1 and DSC3 mRNA 
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levels in the tumour samples and overall mRNA levels in the normal control 
samples (Table 3.1).  This probably reflects variations in expression levels 
between individual patients, coupled with the small number of specimens 
examined, and shows the methodological advantage of comparing expression 
in matched specimens from the same patient (and so eliminating inter-
individual variations).   
 
3.6 Desmoglein expression in colorectal cancer specimens 
At the time of this study, it was not possible to assess desmoglein protein 
levels in colorectal cancer samples because of a lack of desmoglein isoform-
specific antibodies.  However, having investigated DSC1-3 mRNA expression, 
desmoglein expression was also examined by quantitative RT-PCR. Real-
time PCR for DSG1-4 was performed in six matched normal- tumour pairs. 
There was little, if any change in the levels of DSG2 message in any of the 
matched normal-tumour paired samples investigated.  However, all of the 
tumour samples examined did show de novo expression of DSG1, DSG3 and 
DSG4, none of which are normally expressed by colonic mucosa (Fig 3.7). In 
all of the samples examined, de novo expression of desmoglein 1, 3 and 4 
mRNA was more dramatic than that of desmocollins 1 and 3 mRNA.  High 
levels of de novo expression of desmoglein mRNA were not necessarily 
mirrored by high de novo expression of DSC1 and DSC3 mRNA.  Thus, the 
sample showing the greatest ‘inappropriate’ desmoglein response, showed 
little de novo expression of DSC1 and DSC3 mRNA (Fig 3.8). 
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A comparison of mean levels of mRNA in normal samples versus mean levels 
of mRNA in tumour samples was also performed.  No significant decrease in 
DSG2 mRNA levels was obtained by this method.  Similarly no significant 
increase in DSG1 mRNA levels was found.  However, significant increases in 
DSG3 and DSG4 mRNA levels in tumour samples were observed (p<0.05, 
unpaired t test, see Table 3.2).   
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Fig 3.7 Desmoglein mRNA expression patterns in matched specimens of 
histologically normal tissue and tumour material  
 
 
 Desmoglein mRNA expression was measured in 6 matched pairs of normal 
and tumour samples by quantitative RT-PCR. 
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Fig 3.8 Desmocollin and desmoglein mRNA expression patterns in 
matched specimens of histologically normal tissue and tumour material  
 
 
A complete mRNA expression profile for all seven desmosomal cadherins in 
six matched normal and colorectal cancer specimens. 
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Table 3.2 Desmoglein real-time PCR data 
 Normal Tumour P value  
unpaired t test 
 
DSG1 
 
31.9   (± 2.45) 
 
30.5 (±3.43) 
 
CK-8 18.12 (± 1.72) 18.5 (± 1.9)  
ΔCt 13.8   (±2.93) 12   (±4.84) 0.45 
    
DSG2 17.99 (± 0.74) 17.33 (±1.19)  
CK-8 18.62 (± 1.75) 18.67 (± 2.92)  
ΔCt -0.62  (±1.5) -1.34  (±2.24) 0.53 
    
DSG3 30.5  (± 1.62) 24.57 (±2.71)  
CK-8 20.37(± 1.02) 20.75 (± 1.46)  
ΔCt 10.21  (±1.12) 3.81 (±1.74) <0.0001 
    
DSG4 32.25  (± 2.68) 27.56  (± 3.3)  
CK-8 20.3(± 1.02) 20.7(± 1.47)  
ΔCt 11.88  (±1.99) 6.8  (±2.17) 0.0018 
    
 
Table shows mean Ct values (± standard deviation) for 7 normal controls and 
the 7 tumour specimens for DSG1-4  Mean Ct values were also determined 
for internal control CK-8 and subtracted from the mean Ct values for each 
DSG under investigation to give ΔCt value. The ΔCt value for normal and 
tumour samples was compared by t-test.   
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3.7 Discussion 
This investigation has demonstrated reduced DSC2 protein expression in 
colorectal cancer, coupled with de novo expression of those desmocollins that 
are not normally expressed in normal colonic mucosa, i.e. DSC1 and DSC3.  
This is in keeping with the findings of an immunohistochemical study that was 
being carried out at the same time as the work described here.  The combined 
data from these two studies are now published (Khan, Hardy et al. 2006).  A 
previous study on the role of desmosomes in colorectal cancer found no 
evidence for loss of expression of desmocollins (Collins, Taylor et al. 1990), a 
result that clearly conflicts with the data presented herein.  The reason for the 
difference between the two studies is unclear, but it could be attributed to a 
lack of specificity of the antibody used by Collins et al. to detect desmocollin 
protein. The Collins study was performed before it was known that more than 
one desmocollin isoform existed, and it is possible that the antibody that was 
used was pan-specific (i.e. able to detect all three isoforms).  If this is the 
case, loss of DSC2 with compensatory increases in DSC1 and DSC3, would 
give the impression that overall desmocollin expression was unchanged.  In 
this investigation isoform-specific antibodies were used throughout. 
 
In colonic mucosa, DSC2 and DSG2 work together to mediate desmosomal 
adhesion but that is not to say that they are unable to partner other members 
of the desmosomal cadherin family. DSG2 has been previously shown to 
interact with DSC1 in a human fibrosarcoma cell line, HT1080, and mediate 
cell-cell adhesion (Chitaev and Troyanovsky 1997).  Similarly, the co-
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expression of DSC2 with DSG1 and plakoglobin in non-adhesive murine L-
cells resulted in cell-aggregation (Marcozzi, Burdett et al. 1998).   Thus it may 
be that expression of DSC1 and/or DSC3 compensates for loss of DSC2 in 
colorectal cancer with no overall change in desmosomal adhesion.   
 
The loss of DSC2 protein expression does not appear to be accompanied by 
a reduction in DSC2 message levels although more samples would need to 
be examined to definitively rule out transcriptional mechanisms.  The most 
plausible explanation for the loss of DSC2 protein is increased turnover as a 
result of reduced protein synthesis or increased rates of protein degradation, 
perhaps as a result of loss of protein stability.  As a first step in investigating 
this issue, protein half-life, a measure of both synthesis and degradation, 
could be measured in colorectal cancer cell lines by pulse chase experiments, 
using primary colonic cells as the control. 
 
Although correlations were sought with clinicopathological variables, due to 
the small numbers of cancer specimens investigated, it was not possible to 
draw any significant conclusions.  However, having recognised that the 
changes take place, future experiments could involve a greater number of 
patient samples as well as using samples from across the spectrum of 
colorectal neoplasia, from adenoma to all the different stages of invasive 
carcinoma. Identification of where in the sequence of events these changes 
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arise may help to understand the role of desmosomal cadherins in colorectal 
tumourigenesis.   
 
In order to ensure that only high quality protein and RNA were used for these 
experiments, stringent quality control procedures were adhered to.  RNA is 
susceptible to degradation by endogenous and exogenous RNAses, and 
samples were handled in the operating theatre in a standardised manner and 
transferred to liquid nitrogen as soon as possible.  Following RNA extraction, 
samples were visualised on a denaturing gel to ensure the RNA was intact 
prior to further investigation.      Prior to evaluating samples by real-time PCR, 
SYBR Green PCR samples were viewed on gel electrophoresis to ensure that 
the fluorescent signal was due to an amplicon of the correct size rather than 
the generation of primer dimers.  This is a recognised problem associated 
with this technique but can be overcome with careful primer design and 
optimisation of the PCR.  However, it is quick and relatively simple and 
cheaper when compared to the cost of having to design and prepare a 
separate hybridisation probe (e.g. Taqman) for each of the seven 
desmosomal cadherins. 
 
Care must be taken when interpreting real-time PCR results that report a 
difference in relative activity between matched samples, as the calculated 
result may give the impression of more of a difference between 2 samples 
than there actually is.  In addition, as real-time PCR is looking at relative 
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activity, selection of suitable controls may influence the result. A disadvantage 
of using matched normal tissue from the surgical specimen adjacent to the 
tumour is that although it may look macroscopically normal, the cells may 
have been subjected to a ‘field change’.  This phenomenon has been 
recognised in colorectal cancer (Chen, Hao et al. 2004) and if similar changes 
are seen in the tissue surrounding the tumour, an experimental technique that 
reports relative expression may underestimate the difference between the 
tumour and unaffected tissue.  To mitigate this effect, future collection of 
specimens at time of surgery could involve taking biopsies far away from the 
tumour site.  Alternatively, the matched normal tissue samples could be 
compared to a series of samples taken during a normal screening 
colonoscopy, to ensure that the desmosomal cadherin expression profiles 
were similar in both. A third way to overcome this would be to not use 
matched samples from the same individuals, but instead compare the panel of 
tumours to a series of normal samples taken from patients undergoing a 
normal screening colonoscopy. 
 
Real-time PCR most commonly is utilised to assess gene expression levels 
relative to an internal control.  The selection of an appropriate control is very 
important as it should be able to correct for variations in RNA in the sample, 
uneven loading and variations in the experimental conditions (Bustin and 
Mueller 2006). Rubie et al suggest that the ideal internal standard ‘should be 
constitutively expressed by all cell types independent of experimental 
conditions and they should not be affected by any human disease’ (Rubie, 
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Kempf et al. 2005).  Typically housekeeping genes such as glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) and β-actin, as well as 18S ribosomal 
RNA, are used for this purpose but studies in colorectal cancer have shown 
that GAPDH and 18S levels may vary between normal and tumour tissue 
(Rubie, Kempf et al. 2005).  Instead, cytokeratin 8 was used as the internal 
control for the real time PCR and western blotting. It is widely expressed in 
many epithelial tissues and tumours and expression is maintained even in 
advanced colorectal cancer.  It is not expressed by stromal tissue, but exhibits 
identical expression patterns in normal colonic mucosa, primary colonic 
tumours and advanced tumours and metastases (Moll, Franke et al. 1982).  
As a result, cytokeratin 8 can be used to correct for the variable epithelial 
content which may be present in malignant tissue, particularly in advanced 
cancer and has been successfully used as an internal control for real-time 
PCR in a number of studies (Bises, Kallay et al. 2004; Caldwell, Jones et al. 
2004). 
 
Similar precautions were taken with the protein analysis.  Following extraction 
of the protein fraction using Tri-reagent, the matched normal-tumour protein 
samples was subjected to a Biorad assay in order to determine the 
concentration.  Samples were then visualised using SDS-PAGE and stained 
with Coomassie blue to ensure equal loading.  Following transfer onto the 
membrane, Ponceau red stain was used to check the protein bands had been 
successfully transferred.  These techniques were used to ensure that the 
observed differences in protein expression were due to reduced or increased 
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expression rather than experimental errors.  In addition the same samples 
underwent western blotting with cytokeratin 8.  The bands were inspected 
visually for equal loading, as well as being analysed using Image J software. 
 
In general, the de novo increases in desmoglein mRNA expression were 
much greater than that of the desmocollins.  It would be interesting to 
ascertain whether the increases in DSG1, DSG3 and DSG4 mRNA 
expression are accompanied by corresponding increases in protein 
expression.  Isoform-specific antibodies are now commercially available and 
so the next step would be to establish whether desmoglein 1, 3 and 4 proteins 
are present by western blotting, and determine by immunohistochemistry 
whether they co-localise with a desmocollin protein at the cell membrane or 
are redistributed to the cytoplasm.   Desmogleins have a much greater affinity 
for the signalling molecule plakoglobin than the desmocollins (Chitaev, Leube 
et al. 1996) and it may be that de novo expression of desmogleins, or indeed 
desmocollins, affects cell signalling.  One way to test this would be to express 
desmogleins or desmocollins in cultured cells and measure the effects on 
intracellular signal transduction pathways.  It would also be interesting to 
determine whether expression of exogenous desmosomal cadherins in 
cultured cells have any effects on cell behaviour such as proliferation, 
migration or invasion.     
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CHAPTER 4 
INVESTIGATION OF A FUNCTIONAL ROLE FOR DESMOSOMAL 
CADHERINS IN COLORECTAL TUMOURIGENESIS 
 
4.1 Introduction 
As shown in the previous chapter, desmosomal cadherin expression is altered 
in colorectal cancer (Khan, Hardy et al. 2006).  This then raised the question 
as to whether these observed changes were driving the neoplastic process or 
were simply a by-product of it.  The aim of this chapter was to examine the 
effect of loss of normal desmosomal cell adhesion seen in colonic mucosa 
and investigate impact of this on the key features of cancerous growth, 
namely proliferation, invasion and migration.   As desmocollin 2 (DSC2) and 
desmoglein 2 (DSG2) are the only two desmosomal cadherins normally 
expressed in colonic mucosa, the hypothesis of the experiments described in 
this chapter was that if desmosomal cadherins play a role colorectal 
tumourigenesis, then loss of either of these two proteins could result in 
increased proliferation, invasion and migration.  
 
To investigate the loss of DSC2 and DSG2 protein expression an antisense 
cDNA knockdown strategy in cultured epithelial cells was adopted.  The initial 
plan was to use the inducible Tet-On® system (Clontech, BD Biosciences).  
The advantage of this system is that background, or leaky, expression of the 
gene of interest (or antisense cDNA in this case) in the absence of the inducer 
(doxycycline) is very low.  Thus it is possible to carry out transfection 
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experiments in the absence of the inducer, safe in the knowledge that survival 
of cells following transfection will not be compromised by expression of 
antisense RNA. A human breast adenocarcinoma-derived cell line (MCF-7 
Tet-On) expressing the reverse tetracycline-controlled transactivator (rtTA) 
was purchased for this purpose.  An inducible gene expression system can be 
generated by stably transfecting these cells with a plasmid that expresses 
antisense cDNA (or any gene of interest) under the control of a suitable Tet-
response element.  Unfortunately, despite repeated attempts, this series of 
experiments failed to produce stable transfectants following transfection of the 
purchased MCF-7 Tet-On cells with plasmids containing DNA encoding either 
DSC2 or DSG2 antisense cDNA.   
 
Therefore, an alternative strategy was sought.  Still using an antisense RNA 
knockdown method, transfections were carried out using derivatives of the 
plasmid pBATEM2 (see chapter 2.7.1), which had previously been used in the 
laboratory to successfully transfect a number of different cell lines (Tselepis, 
Chidgey et al. 1998).  The disadvantage of the pBAT system compared to the 
Tet-on® system, is that it is not possible to regulate expression of cloned 
genes with this vector.  In this series of experiments, a simple epithelial cell 
line was transfected with pBAT constructs that constitutively expressed either 
antisense DSC2 or DSG2 RNA.  Stable clones were obtained following both 
experiments and these were assessed for the level of knockdown achieved at 
the mRNA and protein level. 
    
91 
 
4.2 Selection of cell lines 
In order to find a suitable cell line for the transfection experiments, four human 
epithelial cell lines, were screened by immunofluorescence microscopy and 
RT-PCR. All four cell lines investigated, CaCo2, HT-29, MCF-7 and LS174T, 
exhibited epithelial morphology, with punctate desmosomal staining at the cell 
membranes when stained with an antibody against the desmosomal protein, 
desmoplakin (Fig 4.1).  These results suggest that all four cell lines express 
all of the proteins necessary for desmosome formation and that these proteins 
are assembled into desmosomes at the cell surface.  
 
RT-PCR (Fig 4.2) confirmed that two of the colonic cancer cell lines (HT-29 
and LS174T) and the breast cancer cell line (MCF-7) expressed only DSC2 
and DSG2 and were therefore considered suitable for further investigation. 
One colonic cell line (Caco-2) expressed low levels of DSC1, as well as DSC2 
and DSG2.  As the presence of DSC1 could potentially compensate for the 
loss of another desmocollin, the effect of DSC2 knockdown could be masked 
by this.  To avoid this source of false-negative results, Caco2 cells were not 
considered to be suitable for these experiments. The other three cell lines 
appeared to be suitable candidates for further investigation.   
 
LS174T was chosen because the adherens junction protein, E-cadherin is not 
expressed by these cells, due to a single base-pair deletion on chromosome 
16q (Efstathiou, Liu et al. 1999).  E-cadherin has long been recognised as a 
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tumour suppressor and loss of E-cadherin expression has been associated 
with invasive features in many different human malignancies (Frixen, Behrens 
et al. 1991), including those of the urinary (Umbas, Schalken et al. 1992) and 
gastrointestinal tracts (Becker, Atkinson et al. 1994), as well as carcinoma of 
the breast, in particular lobular breast cancer (Berx, Cleton-Jansen et al. 
1995).  The intention of using a cell line already deficient in such an important 
cell adhesion protein was to avoid any effect on cell behaviour caused by the 
knockdown of either DSC2 or DSG2 being masked by presence of E-
cadherin. 
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Fig 4.1 Screening of cell lines by immunofluorescence microscopy 
 
 
  
  
 
 
 
 
 
  
LS174
T 
HT-29 MCF-7 
Caco2 
 
Cells were stained with the antibody 11-5F (Parrish, Steart et al. 
1987).  Immunofluorescence microscopy experiments were 
performed by Dr Denise Youngs under my supervision, using 
standard laboratory techniques.  All four cell lines exhibited 
punctuate staining at the membrane, indicative of the presence of 
intact desmosomes.         
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Fig 4.2 Screening of cell lines by semi-quantitative RT-PCR 
 
 
 
 
RNA extracted from human skin was used to prepare cDNA for positive 
controls.  Expected PCR product sizes: DSC1, 400bp; DSC2, 460bp; DSC3, 
600bp; DSG1, 240bp; DSG2, 360bp; DSG3, 350bp; DSG4, 522bp.  The 
yellow arrow highlights a faint band at 400bp in Caco2 cells, demonstrating 
the presence of DSC1 mRNA in these cells.   
 
  
DSC1   DSC2    DSC3    DSG1    DSG2    DSG3     DSG4 
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4.3 Construction of DSC2 antisense plasmids 
DSC2 antisense DNA was cloned into a pBAT vector backbone, derived from 
the plasmid pBATEM2 (Fig 2.1), as follows:  a 824bp human DSC2 cDNA 
fragment was obtained by digestion of a full length human DSC2 cDNA clone 
with restriction enzymes ScaI and BglI (Fig 4.3).  The fragment was blunt-
ended with the Klenow fragment of DNA polymerase I and isolated by electro-
elution (Fig 4.4).  Similarly, a 739bp blunt-ended fragment of human DSC2 
cDNA was obtained by digestion of the full length clone with SphI and NcoI 
(Fig 4.3), followed by treatment with Klenow and electro-elution (Fig 4.4).  The 
5.5 kb pBAT backbone was obtained by digestion of plasmid pBATEM2 with 
BglII and HindIII, followed by blunt ending with Klenow and electro-elution (Fig 
4.4).   
Inserts were ligated into the pBAT backbone using T4 DNA ligase.  Ligation 
mixtures were transformed into competent XL1-Blue bacterial cells and the 
transformed cells plated out onto LB/ampicillin plates.  Individual colonies 
were picked, expanded and plasmid DNA prepared using the alkaline lysis 
method.  Plasmid DNA was screened for the presence of the insert by 
digestion with the restriction enzyme BamHI (Fig 4.5), which linearises the 
pBAT vector backbone.   Clones containing an insert were screened to ensure 
that the insert was in the correct (antisense) orientation by a combination of 
restriction enzyme site mapping and DNA sequencing.   
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Fig 4.3 Diagram showing the DSC2 cDNA sequence and the location of 
the DNA fragments that were cloned into the pBAT vector backbone to 
produce DSC2 antisense constructs 
 
 
 
The figure shows the human DSC2 cDNA sequence (accession number 
NM_024422).  The blue shaded areas indicate the position within the DSC2 
cDNA sequence of DNA that was cloned into the pBAT backbone (in the 
reverse orientation) to produce the two antisense constructs.  The indicated 
restriction enzymes were used to excise the DSC2 fragments.  The yellow 
shaded area indicates the location of DNA used to prepare a probe for the 
detection of DSC2 RNA on northern blots (see section 4.6). 
 
 
Fig 4.4 Ethidium bromide stained agarose gel showing DSC2 and DSG2 
inserts and the pBAT vector backbone following electro-elution 
 
         
             
      Lane 1, 739bp DSC2 insert; lane 2, 824bp DSC2 insert; lane 3, 811bp 
DSG2 insert; lane 4, 825bp DSG2 insert; lane 5, 5.5kb pBAT backbone.   
  1     2      3       4     5  
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Fig 4.5 Screening of DSC2 clones produced by ligation of the 824bp 
DSC2 insert with the 5.5kb pBAT backbone.  
 
  
 
Clones were linearised with BamHI and fragments resolved by agarose gel 
electrophoresis.  Clones C6, C8 and C12 in lanes 6, 8 and 12 respectively 
contain the insert, those in the remaining lanes contain vector alone. 
  
 1   2   3    4    5   6    7   8   9  10  11 12 
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The online software, Webcutter 2.0 
http://www.firstmarket.com/cutter/cut2.html) was used to identify restriction 
enzyme sites within the insert and backbone.  This analysis revealed the 
presence of a PvuII site within the DSC2 cDNA sequence (at position 650).  A 
PvuII site is also present within the SV40 polyadenylation sequence in the 
pBAT backbone (Fig 4.6).  Performing a digest with PvuII allowed the 
orientation of the insert to be ascertained, following ligation into the pBAT 
backbone, as different sized products are generated depending on orientation 
of the insert (Fig 4.6).  Thus digestion with PvuII should yield a 208bp 
fragment if the DSC2 cDNA fragment was inserted into the pBAT backbone in 
the correct (antisense) orientation and a 716bp fragment should result if the 
DSC2 cDNA fragment was inserted in the incorrect (sense) orientation.  Of 
the three clones screened (C6, C8 and C12), one (C8) contained the insert in 
the correct (antisense) orientation (Fig 4.7).  Clone C8 named 
pBATDSC2AS2, was sequenced to unequivocally confirm that the insert was 
in the antisense orientation (Fig 4.8), and used in transfection experiments 
(see below).   
 
A similar restriction mapping strategy was used to establish the correct 
(antisense) orientation of clones obtained following ligation of the 739bp 
(blunt-ended) fragment of DSC2 cDNA into the blunt-ended pBAT backbone.  
Again one clone containing DSC2 in the antisense orientation was identified 
following restriction mapping (not shown).  The clone was named 
pBATDSC2AS1 and sequenced to confirm orientation (Fig 4.8).  
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Fig 4.6 Digestion with PvuII allows orientation of the 824bp DSC2 cDNA 
fragment when cloned into pBAT backbone. 
 
 
The expected products following digestion with PvuII are as follows:   
a.  Antisense orientation:      208bp + 6.1kb 
b.  Sense orientation:    716bp + 5.6kb 
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Fig 4.7 Establishing orientation of the insert produced by ligation of the 
824bp DSC2 fragment with the 5.5kb pBAT backbone  
 
     1        2       3 
 
Screening of clones C6, C8 and C12 for the correct (antisense) orientation by 
digestion with PvuII.  Lane 1, C6; lane 2, C8; lane 3, C12.  Lane 2 contains a 
208bp fragment showing that clone C8 contains the insert in the correct 
(antisense) orientation.  Lanes 1 and 3 contain 716bp fragments showing that 
clones C6 and C12 contain inserts in the incorrect (sense) orientation.  Note 
that in this experiment a double PvuII/BamHI digest was performed so an 
additional 800bp fragment is present in each lane and the size of the vector 
backbone is reduced accordingly.   
 
  
5.3kb 
4.8kb 
 
800bp 
716 bp 
208bp 
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Fig 4.8 Sequencing of pBATDSC2 AS2 and pBATDSC2 AS1 constructs  
 
a. pBATDSC2AS2 
 
b. pBATDSC2AS1 
 
Data was obtained using a sequencing primer 
(TGTGGCCTCGAACACCGAG) that hybridises to the HSV TK promoter in the 
pBAT backbone.  Results were aligned with DSC2 sequence (NM_024422) 
using the Blast/Align online tool (http://blast.ncbi.nlm.nih.gov/).  Peaks 
representing the 4 different nucleic acids as follows:  red, thymine (T); green, 
adenine (A); blue, cytosine (C); black, guanine (G).    
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4.4 Construction of DSG2 antisense plasmids 
The following procedure was used to produce two DSG2 antisense vectors for 
use in the DSG2 knockdown experiments.  Fragments of the human DSG2 
cDNA sequence (Fig 4.9) were amplified by RT-PCR using RNA extracted 
from human skin as starting material.  An 811bp fragment was amplified using 
primer pair DSG2AS2 and an 825bp fragment was amplified using primer pair 
DSG2AS1 (Table 2.5).  The amplified fragments were cloned into the XcmI 
cut pDK101 and sequenced to ensure that no unexpected base changes were 
introduced into the DNA during PCR amplification.  Each set of primer pairs 
were designed to incorporate SalI and BamHI restriction enzyme sites.  This 
allowed the fragments to be released from the pDK101 vector by digestion 
with these restriction enzymes.  Following digestion the fragments were blunt 
ended with Klenow and isolated by electro-elution (Fig 4.4).  Each fragment 
was then ligated into the 5.5kb blunt ended pBAT backbone.  Ligation 
mixtures were transformed into competent XL1-Blue bacteria, and individual 
clones screened for the presence of the insert, and for orientation, as 
described in Section 4.2.  Clones pBATDSG2AS2 and pBATDSG2AS1, 
containing 811 and 825bp DSG2 antisense fragments respectively, were then 
used for DSG2 knockdown experiments in LS174T cells.   
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Fig 4.9 Diagram showing the DSG2 cDNA sequence and the location of 
the DNA fragments that were cloned into the pBAT vector backbone to 
produce DSG2 antisense constructs 
 
 
 
The figure shows the human DSG2 cDNA sequence (accession number 
NM_001943).  The red shaded areas indicate the position within the DSG2 
cDNA sequence of DNA that was amplified by PCR and cloned into the pBAT 
backbone (in the reverse orientation) to produce the two antisense constructs.  
The yellow shaded area indicates the location of DNA used to prepare a 
probe for the detection of DSG2 RNA on northern blots (see section 4.6). 
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4.5 Transfection of LS174T cells with DSG2 and DSG2 antisense 
plasmids 
LS174T cells were transfected as described (Section 2.11.1) with either 10µg 
of each of the two DSC2 antisense plasmids (pBATDSC2AS2 and 
pBATDSC2AS1), or 10µg of each of the two DSG2 plasmids (pBATDSG2AS2 
and pBATDSG2AS1), as well as 2.5µg of the plasmid pBATneo, which 
confers resistance to the antibiotic G418.  A third transfection was performed 
with 2.5µg of the plasmid pBATneo alone. Colonies were obtained in all three 
experiments following selection with G418.  Of these, 42 antisense DSC2, 40 
antisense DSG2 and 8 control clones were picked and expanded.   
 
4.6 DSC2 and DSG2 RNA expression in transfected cells 
RNA was extracted from each of the 90 LS174T clones as described in 
section 2.4. These samples examined by denaturing gel electrophoresis to 
ensure RNA quality and equal loading (Fig 4.10).  Staining with ethidium 
bromide and examination under UV light before and after transfer onto 
nitrocellulose membrane was performed to ensure transfer of RNA onto the 
membrane.  Blots were then screened to determine whether knockdown of 
either DSC2 or DSG2 had been achieved by transfection of the cells with the 
antisense constructs.  In order to carry out northern blotting experiments, it 
was necessary to first develop probes for detection of DSC2 and DSG2 
mRNA. 
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Fig 4.10 Denaturing gel electrophoresis to check quality of RNA from 
cells transfected with antisense constructs   
  
 
Ethidium bromide stained gel showing the presence of undegraded 28S and 
18S ribosomal RNA. Lane1, RNA Ladder; lanes 2-4, RNA from three clones 
co-transfected with pBATDDSC2AS1, pBATDSC2AS2 and pBATneo; lanes 5-
6, RNA from three clones co-transfected with pBATDSG2AS1, 
pBATDSG2AS2 and pBATneo; lane 7, RNA from one clone transfected with 
pBATneo alone. 10µg RNA was loaded per lane. 
 
  
28S rRNA 
 
 
18S rRNA 
 
 
 
    1           2          3          4           5          6          7  
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4.7 Generation of DSC2 and DSG2 northern probes 
Probes were designed to identify DSC2 and DSG2 mRNA on northern 
blotting.  Using cDNA made from LS174T RNA as starting material, a 460bp 
fragment of DSC2 and a 360bp fragment of DSG2 cDNA were amplified by 
PCR, using the primers listed in Table 2.3 and PCR conditions described in 
section 2.5.2.  The locations of these fragments within the DSC2 and DSG2 
cDNA sequences are indicated in figures 4.3 and 4.9 respectively.  The PCR 
products were electro-eluted and then ligated with XcmI cut pDK101.  Ligation 
mixtures were transformed into competent XL1-Blue cells and transformed 
cells grown on LB/ampicillin plates.  Mini-prep DNA extraction was performed 
and the DNA linearised with EcoRV to identify colonies which had taken up 
the insert (Fig 4.11).  A number of clones with inserts were identified.  Of 
these, one containing a DSC2 insert and one containing a DSG2 insert was 
sequenced to confirm the identity of the insert DNA.  Sequenced inserts were 
released from the vector backbone by digesting with enzymes AatII and SacII.  
The AatII/SacII fragments were then isolated by electro-elution (Fig 4.12) and 
labelled with radio-active 32P (see section 2.5.5). 
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Fig 4.11 Development of northern probes: screening of clones produced 
by ligation of the DSC2 and DSG2 PCR products with pDK101  
 
 
 
Lanes 1-6, DNA from clones obtained following ligation of the DSC2 PCR 
product with pDK101; lane 7, pDK101 DNA; lanes 8-13, clones obtained 
following ligation of the DSG2 PCR product with pDK101.  DNA was 
linearised with EcoRV.  Lanes 4 and 6 contain plasmids that have taken up 
the 460bp DSC2 insert and lanes 8 and 9 contain plasmids that have taken up 
the 360bp DSG2 fragment.  The arrow indicates the size of the pDK101 
backbone (3kb).   
 
Fig 4.12 Development of northern probes:  electro-eluted DSC2 and 
DSG2 cDNA prior to labelling with radioactive isotope 
 
         
Ethidium bromide-stained agarose gel showing electro-eluted DNA isolated 
following digestion of pDK101 clones with DSC2 and DSG2 inserts with AatII 
and SacII. Lane 1, λ HindIII markers; lane 2, DSC2 (460bp); lane 3 DSG2 
(360bp).  
       1        2 
  1    2     3    4    5    6     7   8     9   10   11  12  13  
λHindII
I 
1        2        3 
 460bp 
 
 
360bp 
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4.8 Assessment of DSC2 and DSG2 RNA knockdown by northern 
blotting 
Once the RNA from the cells transfected with the DSC2 or DSG2 antisense 
plasmids  had been transferred onto the nitrocellulose membrane and probed 
with the 32-P labelled DSC2 or DSG2 probes respectively, the membranes 
were exposed to auto-radiography film for at least 1 week.   Screening by 
northern blotting identified 10 clones in which the DSC2 antisense plasmid 
appeared to have decreased DSC2 mRNA expression (Fig 4.13).  Ten clones 
with reduced DSG2 mRNA expression were also identified in this manner (Fig 
4.14).   
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Fig 4.13 Northern blot of RNA from clones transfected with antisense 
DSC2 plasmids 
 
 
This northern blot demonstrates reduced DSC2 mRNA in lanes 1, 2, 4, 7, 8, 
10 and 11 compared to the control RNA from cells transfected with pBATneo.  
10µg of RNA was loaded per lane.  Visualisation of the gel with ethidium 
bromide both before and after transfer of RNA were utilised to ensure that the 
observed differences were not due to variations in RNA loading.   The arrow 
(lane 2) indicates the sample with the greatest DSC2 knockdown by real-time 
PCR (lane 1, Fig 4.15).  In all 10 of the 42 LS174T clones successfully 
transfected with DSC2 antisense constructs showed reduced DSC2 RNA 
expression by northern blotting. 
 
 
Fig 4.14 Northern blot of LS174T clones transfected with antisense 
DSG2 plasmids 
 
 
 
This northern blot demonstrates reduced DSG2 mRNA expression in lanes 1, 
4, 6 and 8 compared to control RNA from cells transfected with the control 
plasmid, pBATneo.  The same precautions utilised for the DSC2 experiments 
to ensure equal loading (see legend to Fig 4.13) were used. The arrow (lane 
1) corresponds to the sample with the greatest DSG2 knockdown by real-time 
PCR (lane 4, Fig. 4.16).  In all, 10 of the 40 LS174T clones successfully 
transfected with DSG2 antisense constructs showed reduced DSG2 RNA 
expression by northern blotting. 
  
   1    2    3     4    5     6    7     8    9   10  11 Control 
  1       2      3     4      5      6      7      8      9    Control 
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4.9 Assessment of DSC2 and DSG2 knockdown by real-time quantitative 
RT- PCR 
Real-time PCR was used to quantify the amount of target knockdown 
achieved by the expression of the DSC2 or DSG2 antisense plasmids.  The 
10 DSC2 clones and 10 DSG2 clones  identified as showing reduced RNA 
expression by northern blotting were investigated by real-time PCR as 
described in section 2.5.1 with the primers detailed in Table 2.2.  The results 
obtained were first normalised against cytokeratin 8, in order to correct for any 
variations in RNA content in the initial RT reaction.  DSC2 and DSG2 mRNA 
expression in the transfected cells was then compared to the expression 
observed in the control transfection (with pBATneo).   
 
Of the ten samples assessed for DSC2 mRNA knockdown, mRNA expression 
was essentially unchanged in 5 (expression levels 0.8-1.2), when compared 
to the control.  These expression levels were regarded as unchanged, as they 
were unlikely to result in an appreciable change in expression of the DSC2 
protein.  Four of the DSC2 knockdown samples investigated in this manner 
showed reduced DSC2 mRNA expression (0.4-0.7 of control).  The maximum 
DSC2 knockdown achieved was 60%, i.e. DSC2 expression was 40% of the 
control mRNA expression (Fig 4.15, sample 1).  
 
The ten clones identified by northern blotting as having reduced DSG2 RNA 
expression were also investigated by real-time PCR.  Six of these showed 
unchanged mRNA expression. Reduced mRNA expression was seen in 4/10 
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samples (0.45-0.75 of control). The maximum DSG2 knockdown achieved 
was 55%, i.e. DSG2 expression was 45% of the control mRNA expression 
(Fig 4.16, sample 4). 
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Fig 4.15 Quantification of DSC2 knockdown in transfected LS174T cells 
by real- time RT-PCR 
 
 
                 
 
 
Ten clones with reduced DSC2 mRNA expression by northern blotting were 
assessed by real-time PCR.  All experiments were performed in triplicate with 
positive and negative controls.  All results are expressed as a ratio of the 
DSC2 expression observed with the control (LS174T cells transfected with 
pBATneo).  The sample in lane 1 corresponds to the sample that showed the 
greatest DSC2 knockdown by northern blotting (lane 2 in Fig 4.13).  
 
 
 
 
  
Relative  
expression 
Sample number  
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Fig 4.16 Quantification of DSG2 knockdown in transfected LS174T cells 
by real- time PCR 
 
                 
Ten DSG2 clones with reduced DSG2 RNA expression by northern blotting 
were assessed by real-time PCR.  All experiments were performed in triplicate 
with positive and negative controls.  All results are expressed as a ratio of the 
DSG2 expression observed with the control (LS174T transfected with 
pBATneo).  The sample in lane 4 corresponds to the sample that showed the 
greatest DSG2 knockdown by northern blotting (lane 1 in Fig 4.14).  
 
 
Relative  
expression 
Sample number 
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4.10 Protein expression in transfected LS174T cells 
Western blotting was used to assess whether the degree of mRNA 
knockdown achieved in antisense transfection experiments was sufficient to 
alter protein expression.  Protein was extracted from those 10 clones that 
showed reduced DSC2 mRNA expression by northern blotting following 
transfection with the DSC2 antisense constructs.  Protein was resolved by 
SDS-PAGE and DSC2 protein detected with an anti-DSC2 antibody following 
western blotting onto nitrocellulose.  No change was seen in DSC2 protein 
levels, in any of the ten clones (Fig 4.17).  Similarly, those 10 clones that 
showed reduced expression of DSG2 mRNA by northern blotting were 
investigated by western blotting with an anti-DSG2 antibody.  Again, no 
change was seen in DSG2 protein levels (Fig.4.18). 
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Fig 4.17 DSC2 protein expression in LS174T clones transfected with 
DSC2 antisense constructs  
 
 
 
 
Protein (10μg) from cell lysates was resolved on a 8% SDS-polyacrylamide 
gel.  DSC2 expression was detected using an anti-DSC2 antibody.  Lanes 1-2 
contain protein from control clones; lanes 3-9 contain protein from 7 DSC2 
knockdown clones.  This blot initially gives the impression that DSC2 protein 
is reduced in sample 3 and sample 7.  However, the cytokeratin 8 protein 
expression is also reduced suggesting that the perceived differences are 
actually due to variations in protein loading rather than reduced DSC2 protein 
expression.  Note that lanes 3, 4, and 5 contain protein from those clones 
shown by real-time PCR to have the greatest reduction in DSC2 mRNA 
expression.  The molecular weight of the DSC2 protein is 120kDa and that of 
cytokeratin 8(CK-8) is 52kDa. 
  
Fig 4.18 DSG2 protein expression in LS174T cells transfected with DSG2 
antisense constructs 
 
 
 
 
DSG2 expression was detected using an anti-DSG2 antibody.  Lane 1 
contains protein from a control clone; lanes 2-4 contain protein from 3 DSG2 
knockdown clones.  The blot was reprobed with an anti-cytokeratin 8 antibody 
to ensure equal loading (not shown).  Molecular weight of the DSG2 protein is 
160kDa. 
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4.11 Discussion 
The outcome of this series of experiments was that although a reduction in 
the level of DSC2 and DSG2 mRNA was achieved, this was not sufficient to 
result in a change of protein expression.  As a result, the planned 
investigations into the effect of loss of DSC2 and DSG2 adhesion proteins in 
epithelial tumourigenesis were not pursued.  Had the antisense experiments 
resulted in a reduction of either DSC2 or DSG2 protein expression, the 
intention was to assess the impact of knockdown on desmosome structure 
(using immunofluorescence, confocal and electron microscopy) and cell 
phenotype (by proliferation, migration and survival assays). 
  
The initial strategy was to use an inducible system to knockdown the DSC2 
and DSG2 targets.  One advantage of using the Tet-On® system is that the 
antisense plasmids would have been turned off until the inducer doxycycline 
was added to the culture medium.  Another is that doxycycline can induce 
target gene expression in a dose-dependent manner.  The Tet-On® system is 
also reversible, unlike some other inducible systems, on withdrawal of the 
inducer.  The Tet-systems are able to regulate gene expression very closely 
and reduce background ‘leaky’ expression, which was a potential shortcoming 
in a previous antisense DSC2 knockdown study, which employed a 
dexamethasone-inducible system (Roberts, Burdett et al. 1998).  It is unclear 
why the system did not work in our case.  The purchased MCF7 Tet-On cells 
grew as expected until transfected with the DSC2 or DSG2 antisense 
constructs, after which no colonies were established.  The cells died before 
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any doxycycline had even been added to the experiment, ruling this out as a 
source of potential toxicity. The antisense cDNAs were later successfully 
transfected into LS174T cells so it is unlikely they were intrinsically lethal to 
mammalian cells.   
 
Despite the successful transfection of LS174T cells with the antisense 
plasmids, using the non-inducible system, the observed level of DSC2 and 
DSG2 RNA knockdown did not translate to an appreciable difference in 
protein expression.  One possible explanation for this is that the transfection 
was actually highly successful at achieving knockdown, but that this situation 
was not compatible with cell survival, thus allowing only cells with lower levels 
of knockdown to survive. Previous studies have shown that at least one 
desmocollin and one desmoglein must be present for normal desmosomal 
adhesion to take place (Marcozzi, Burdett et al. 1998; Tselepis, Chidgey et al. 
1998), and that knockout of Dsg2 in mice results in embryonic lethality 
(Eshkind, Tian et al. 2002).  It is therefore possible, in simple epithelial cell 
line such as LS174T which only expresses one desmocollin (i.e. DSC2) and 
one desmoglein (i.e. DSG2), that if either of these components is lost the cell 
cannot survive.  
 
Alternative strategies to the one we adopted would have been to use 
antisense oligonucleotides or RNA interference, in the form of siRNA.  Both 
methods mediate gene knockdown by binding to the target RNA in a 
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sequence-specific manner but they achieve gene silencing by different routes.  
Antisense oligonucleotides usually are made up of 15-20 nucleotides and 
although various mechanisms have been described, the most widely adopted 
and often the most effective forms of antisense knockdown employ either 
RNase-H mediated cleavage to break down the mRNA in question or 
inhibition of  its translation (Achenbach, Brunner et al. 2003).  Although this 
represents a relatively simple concept, in practice, antisense oligonucleotide 
technology is anything but simple.  One study found that only 1 in 8 antisense 
oligonucleotides are able to bind effectively and specifically to the target 
mRNA (Stein 2001).  A number of reasons contribute to this, including the 
target sequences not being accessible due to secondary and tertiary 
structures formed by long RNA molecules and instability of unmodified 
oligodeoxynucleotides due to degradation by endogenous nucleases.  In 
addition, low affinity of the antisense oligonucleotide for the target may require 
higher concentrations, leading to toxicity (Kurreck 2003).  RNA interference 
utilises the dicer enzyme to cleave double stranded RNA molecules into 
shorter fragments of RNA, which bind to the target mRNA with the 
complimentary sequence, initiating its degradation.  RNA interference is now 
routinely used and would be the technique of choice in any future attempts to 
knockdown DSC2 or DSG2.   
 
With the benefit of hindsight, a potential false negative result must also be 
considered.  The antibody used for the detection of the DSG2 protein, 33-3D, 
is also capable of detecting the cytoplasmic tail of DSG1 (Vilela 1995, Krunic 
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1998).  When the experiment was originally conceived and undertaken this 
did not present a problem as LS174T cells only express one desmoglein 
(DSG2) and the hypothesis was to examine the effects of loss of this protein. 
Now that there is evidence for desmosomal cadherin switching in colorectal 
cancer (Khan et al 2006), it is important to consider the possibility that de 
novo expression of DSG1 may have occurred in the knockdown cells masking 
any loss of DSG2 (as detected with antibody 33-3D).  This could now be 
addressed by using a DSG1 and DSG2 specific antibodies, as well as looking 
for upregulation of DSG1 at a transcriptional level.  
 
As cadherin switching has now been recognised in both classical (Hazan, 
Phillips et al. 2000; Tomita, van Bokhoven et al. 2000) and desmosomal 
cadherins (Khan et al. 2006) any future knockdown studies, perhaps using 
RNA interference, should include investigation of DSC1 and 3 and DSG1 and 
3 at both the protein and RNA levels.  The desmosomal cadherin genes form 
a tight cluster on chromosome 18q (Hunt, Sahota et al. 1999), suggesting that 
their transcription could be regulated in a coordinated fashion.  Little is known 
about the regulation of desmosomal cadherin gene expression and this will 
comprise the area of investigation for the next chapter. 
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 CHAPTER 5 
REGULATION OF DESMOSOMAL CADHERIN GENE EXPRESSION IN 
COLON CANCER CELLS 
 
5.1 Introduction 
Little is known about the regulation of desmosomal cadherin gene expression 
in colonic cells.  However, the CCAAT/enhancer binding protein (C/EBP) 
family has previously been shown to influence desmosomal cadherin gene 
expression in mouse keratinocytes (Smith, Zhu et al. 2004).  The C/EBPs 
belong to the basic leucine-zipper class of transcription factor (Vinson, Sigler 
et al. 1989).  To date, six members (C/EBP α-ζ) of this family have been 
described, which share both structural and functional similarities (Lekstrom-
Himes and Xanthopoulos 1998).  Expression of the C/EBP isoforms has been 
shown to change throughout the development of a number of different tissues, 
as well as in response to injury (Ramji and Foka 2002).  The C/EBPs appear 
to play a role in the regulation of gene expression in colonic development.   
C/EBPα is involved in growth arrest and terminal differentiation in the 
embryonic mouse intestine (Chandrasekaran and Gordon 1993) and  
C/EBPα, C/EBPβ and C/EBPδ all demonstrate altered expression  patterns in 
the  post-natal development of murine colonic cells (Blais, Boudreau et al. 
1995).   
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The aim of the experiments described in this chapter was to determine 
whether C/EBPs are important in the regulation of DSC2 and DSG2 gene 
expression in the colon.  Firstly, the effect of C/EBPs on desmosomal 
cadherin promoter activity in the colonic cancer cell line, Caco2 was explored.  
To achieve this, fragments of the DSC2 and DSG2 promoters were cloned 
into a vector containing a luciferase reporter gene.  DNA encoding various 
C/EBP isoforms was then co-transfected into Caco2 cells with the reporter 
constructs, and their effect on luciferase activity measured.  Secondly, 
experiments were carried out to investigate the possibility that up-regulation of 
C/EBPs in colorectal cancer is responsible for the aberrant expression of 
DSC1 and DSC3 that occurs in colorectal cancer specimens (Chapter 3).  
Finally, investigations were performed to determine the role of other 
transcription factors with putative binding sites in the DSC2 and DSG2 
promoters in the regulation of expression of these genes in Caco2 cells.   
 
 
5.2 Identification of consensus binding sites within the DSC2 and DSG2 
promoters 
The promoter sequences  of the desmosomal cadherin genes DSC2 
(accession number Y08431) and DSG2 (accession number  AJ278448) was 
scrutinised using MatInspector v2.2 software (Quandt, Frech et al. 1995), in 
order to identify putative transcription factor binding sites. The sequences of 
over 100 binding sites were identified in this manner, including those for 
C/EBPs, AP1, AP2, AP4, TCF/LEF1 and p53 (Tables 5.1 and 5.2).    
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Table 5.1 Positions of putative transcription factor binding sites relative 
to the ATG initiation codon in the DSC2 promoter 
 
Transcription Factor Position 
C/EBP -285, -665, -735, -825, -928 
AP1 -452, -541, -585, -611, -695, -751, -863, -924 
AP2 -60, -505,-538 
AP4 -99, -359, -443, -508, -594 
TCF-LEF1 -165, - 695  
p53 -20, -433, -500, -757 
 
 
Table 5.2 Positions of putative transcription factor binding sites relative 
to the ATG initiation codon in the DSG2 promoter 
 
Transcription Factor Position 
C/EBP -645, -666, -808, -935, -957 
AP2 -31, -101, -181, -549,  
TCF-LEF1 -844, -895 
p53 -686, -691, -702 
 
NB. No binding sites were identified for AP1 or AP4 within the 1000 bases 
proximal to the ATG codon. 
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Fig 5.1  Location of the primers used to amplify fragments of the DSC2 
promoter  
  
 
 
 
 
 
 
 
 
 
 
Fig 5.2  Locations of the primers within the DSG2 promoter sequence 
 
 
 
 
 
 
 
 
 
 
 
 
 
The location of the primers used to amplify residues -1 to -999 and -1 to -
563 of the DSC2 promoter are shown.  Amplified DNA was cloned into 
vector pGL3-Basic    to produce reporter plasmids pGL3BDSC2(1kb) and 
pGL3BDSC2(500) respectively.  The larger fragment was also cloned into 
pGL2-Enhancer to produce plasmid pGL2EDSC2(1kb). 
 
 
 
 
 
 
Primers used to amplify residues -1 to -999 and -1 to -563 of the DSC2 
promoter are shown.  These sequences were cloned into vector pGL3-
Basic    to produce reporter plasmids pGL3BDSC2(1kb) and 
pGL3BDSC2(500) respectively.  The larger fragment was also cloned into 
pGL2-Enhancer to produce plasmid pGL2EDSC2(1kb). 
 
ATG 
DSC2(1kb) Forward primer                  DSC2(500) Forward primer                  
-999                                                         -563                                      -1     +1 
                                                                                       
                                                                                           DSC2 Reverse primer 
 
 
 
 
 
 
The location of primers used to amplify residues -1 to -1061 and -1 to -501 
of the DSG2 promoter are shown.  Amplified DNA was cloned into vector 
pGL3-Basic    to produce reporter plasmids pGL3BDSG2(1kb) and 
pGL3BDSG2(500) respectively.  The larger fragment was also cloned into 
pGL2-Enhancer to produce plasmid pGL2EDSG2(1kb). 
 
 
 
 
Primers used to amplify residues -1 to -1061 and -1 to -501 of the DSG2 
promoter are shown.  These sequences were cloned into vector pGL3-
Basic    to produce reporter plasmids pGL3BDSG2(1kb) and 
DSG2(1kb)Forward primer                  DSG2(500) Forward primer                  
      -1061                                      -501                                   -1   +1    
                                                                             
                                                                         DSG2 Reverse Primer 
ATG 
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5.3 Construction of reporter plasmids 
DNA was prepared from the yeast artificial chromosome (YAC) clones 14E-B5 
(DSC2) and 9G-C3 (DSG2).  Fragments upstream of the DSC2 and DSG2 
genes were then amplified by PCR using YAC DNA as starting material and 
the oligonucleotides described in Table 2.5 (and shown in Figures 5.1 and 
5.2).  Figure 5.3 shows the results of the PCR amplification of the DSC2 
promoter fragments.   
DSC2 and DSG2 PCR products were cut with KpnI-XhoI and ligated into 
KpnI-XhoI cut pGL3Basic reporter plasmid, to yield pGL3BDSC2(1kb), 
pGL3BDSC2(500), pGL3BDSG2(1kb) and  pGL3DSG2(500).  Similarly, KpnI-
XhoI fragments were inserted into KpnI-XhoI cut pGL2Enhancer to yield 
pGL2EDSC2(1kb) and pGL2EDSG2(1kb).  All inserts were sequenced to 
ensure that no mutations had been inadvertently introduced during PCR 
amplification.  The sequenced plasmid DNA was then used in transient 
transfection experiments in cultured Caco2 cells.   
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Fig 5.3 Amplification of the DSC2 promoter by PCR 
 
 
Agarose gel showing the PCR products obtained from the DSC2 YAC clone 
14E-B5 to yield two fragments of the DSC2 promoter, 998 bases (lanes 1 and 
2) and 562 bases (lanes 3 and 4) upstream of the ATG initiation codon.  The 
two PCR reactions were carried out with two different DNA concentrations: 
10ng per reaction (lanes 1 and 3) and 1ng per reaction (lanes 2 and 4).  
12.5µl of each PCR reaction was loaded onto the gel. 
 
←1000bp 
←500bp 
1     2     3     4  
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5.4 Transfections of Caco2 cells with reporter constructs 
Initial experiments were used to establish baseline activity of the promoter 
constructs in the colonic cancer cell line, Caco2. The pGL3-Basic plasmids 
contain no eukaryotic promoter or enhancer sequences.  Thus insertion of the 
promoter element under investigation upstream of the luciferase gene allows 
its activity to be monitored by measuring luciferase expression.  The pGL2-
Enhancer vector contains an SV40 enhancer element downstream of the 
luciferase gene, which results in increased luciferase transcription.  The 
luciferase activity was greater with the enhancer constructs, however 
adequate luciferase activity was recorded with all the pGL3-Basic promoter 
constructs (Fig 5.4) and therefore the pGL3-Basic reporter plasmids were 
used in preference to the pGL2-Enhancer reporter constructs for the 
subsequent experiments.  Both DSG2 constructs showed greater baseline 
activity than the DSC2 plasmids. The longer DSC2(1kb) fragment showed 
greater activity the DSC2(500) fragment, however the opposite was observed 
with the DSG2 constructs.  This may be due to the presence of negative 
regulatory elements situated in the distal portion of the DSG2 (1kb) promoter 
fragment. 
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Fig 5.4  Baseline luciferase activity in DSC2 and DSG2 reporter plasmids 
a. pGL3-Basic reporter plasmids   
 
b.  pGL2-Enhancer reporter plasmids                     
 
Luciferase reporter plasmids were constructed using fragments of the DSC2 
and DSG2 promoters.  Caco2 cells were transiently transfected with reporter 
plasmids and firefly-luciferase activity measured after 48h.  Transfection 
efficiency was monitored with plasmid pRL-TK (Fig 2.3).  Each bar represents 
the means +/- SD for two experiments carried out in triplicate.   
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5.5 Effect of C/EBPs on DSC2 promoter activity 
To examine the effect of C/EBPs on desmosomal cadherin promoter activity 
reporter constructs were co-transfected into Caco2 cells with pcDNA-based 
expression plasmids encoding a variety of C/EBP transcription factors.  In 
initial experiments the longer DSC2 reporter construct, containing bases -1 to 
-999 of the DSC2 promoter, was used.  C/EBPs α and ζ (CHOP) had no effect 
on luciferase activity when compared to the empty expression vector pcDNA3 
(Fig 5.5a).  However, both C/EBPβ and C/EBPδ had a significant activating 
effect, with C/EBPβ causing a 4.2-fold increase in promoter activity and 
C/EBPδ causing a 1.8-fold increase in activity.  With the shorter DSC2 
reporter construct, containing bases -1 to – 563 of the DSC2 promoter, 
C/EBPβ retained its transactivating ability, albeit with 30% reduction (Fig 
5.5b). This suggests that an important binding site for C/EBPβ lies in the first 
563 bases upstream of the ATG codon. The ability of C/EBPδ to activate the 
DSC2 promoter was abrogated with the shortened reporter plasmid, 
suggesting that transactivation by C/EBPδ is due to interactions taking place 
at a binding site in the distal part of the DSC2 (1kb) promoter construct.    
 
5.6 Effect of C/EBPs on DSG2 promoter activity 
C/EBPs α, β, and δ all significantly activated the DSG2(1kb) promoter, with 
C/EBPα responsible for a 2.2-fold increase in activity, C/EBPβ responsible for 
a 3.8-fold increase in activity and C/EBPδ responsible for a 2.7-fold increase 
in activity (Fig 5.6a).  Interestingly, C/EBPζ (CHOP) significantly repressed the 
DSG2 promoter to only 60% of the baseline activity.  C/EBPζ shares the 
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leucine zipper with other C/EBP members and thus can form heterodimers 
with them. But although C/EBPζ is able to interact with other C/EBP family 
members, it lacks the C/EBP DNA-binding recognition sequence and thus 
acts as a functional repressor of C/EBP activity (Ron and Habener 1992).  
Thus it may be that endogenous Caco2 C/EBPs contribute to promoter 
activity that is seen in the absence of exogenous transcription factors (Fig 5.4) 
and that these are inhibited by exogenous C/EBPζ.  When the reduced length 
promoter construct was used in transfection experiments, the effects seen 
with all the C/EBPs tested were decreased (Fig 5.6b).  Only C/EBPβ showed 
statistically significant activity above baseline.  This activity was reduced by 
approximately 30% when compared to the DSG2(1kb) promoter construct.  
MatInspector only identified C/EBP binding sites within the distal part of the 
DSG2 promoter sequence so it may be that C/EBPβ transactivates the 
DSG2(500) reporter plasmid via a site that is not recognised by the 
programme.   
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Fig 5.5 Effect of C/EBPs on DSC2 promoter activity 
a. pGL3BDSC2(1kb) reporter plasmid 
 
b. pGL3BDSC2(500) reporter plasmid 
 
Luciferase reporter plasmids were co-transfected into Caco2 cells with either 
empty expression plasmid pcDNA3 or pcDNA3 plus C/EBP α, β, δ and ζ 
cDNAs.   Activity is shown relative to the empty vector pcDNA3, which has 
been given a reference value of 1. *p<0.05, **p<0.0001. 
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Fig 5.6 Effect of C/EBPs on DSG2 promoter activity 
 
a. pGL3BDSG2(1kb) reporter plasmid 
 
b. pGL3BDSG2(500) reporter plasmid 
 
Luciferase reporter plasmids were co-transfected into Caco2 cells with either  
empty expression plasmid pcDNA3 or pcDNA3 plus C/EBP α, β, δ and ζ 
cDNAs.   Activity is shown relative to the empty vector pcDNA3, which has 
been given a reference value of 1. *p<0.05, **p<0.0001. 
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5.7 Effect of C/EBPs on Dsc1 and Dsc3 promoter activity in Caco2 cells 
Having previously demonstrated that the desmosomal cadherins not normally 
expressed in colonic cells, are aberrantly expressed in colorectal cancer 
(Chapter 3), we carried out preliminary experiments to identify transcription 
factors that may activate DSC1 and DSC3 gene expression in colorectal 
cancer cells.  Human DSC1 and DSC3 promoter constructs were not 
available so as a first step we used murine promoter constructs that had been 
used in a previous study on the regulation of Dsc1 and Dsc3 activity in the 
epidermis (Smith, Zhu et al. 2004).  In the case of Dsc1 the construct 
consisted bases -1 to -417bp of the mouse Dsc1 gene cloned into the plasmid 
pGL3-Enhancer, upstream of the luciferase reporter gene.  A similar construct 
containing bases -1 to -293 from mouse Dsc3 in pGL3-Basic was used.   
 
C/EBPα and C/EBPβ both significantly stimulated transcription from the Dsc1 
and Dsc3 promoters in human Caco2 cells.  C/EBPδ also activated the Dsc3 
promoter but not the Dsc1 promoter.  C/EBPα had the greatest effect out of 
the three C/EBPs tested, on both the Dsc1 and Dsc3 promoters.  Although 
C/EBPs influence DSC2 promoter activity, it appears that they have a much 
greater effect on desmocollins not typically expressed in normal colonic 
epithelium.  The Dsc3 promoter appeared to be the most influenced by the 
C/EBPs, showing a 20-fold increase and 24-fold increase above base-level in 
response to C/EBPα and C/EBPβ respectively.  Although preliminary, these 
results do show a potential mechanism for the activation of desmosomal 
cadherins in colorectal cancer as up-regulation of either C/EBPα or β in 
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colorectal cancer cells could potentially lead to a dramatic increase in 
expression of DSC3 in particular.   
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Fig 5.7 Effect on C/EBPs on Dsc1, DSC2 and Dsc3 promoter activity 
 
 
Luciferase reporter plasmids were co-transfected into Caco2 cells with either 
empty expression plasmid pcDNA3 or pcDNA3 plus C/EBP α, β, δ and ζ 
cDNAs.   Activity is shown relative to the empty vector pcDNA3, which was 
given a reference value of 1 (not shown). *p<0.05.   
0.00
5.00
10.00
15.00
20.00
25.00
30.00
pGL2E-
DSC1(417)
pGL3B-
DSC2(1kb)
pGL3B-
DSC3(293)
* 
* 
* 
* 
* 
* 
* 
α                               β                              δ 
135 
 
5.8 Effect of activator protein-1 (AP1) transcription factors on DSC2 and 
DSG2 promoter activity  
Putative binding sites for a variety of transcription factors were detected in the 
DSC2 and DSG2 promoters by the MatInspector programme (Tables 5.1 and 
5.2).  Hence experiments were performed to compare the transactivating 
ability of these transcription factors with that of the C/EBPs.  A number of AP1 
binding sites were identified by the MatInspector programme in the DSC2 
promoter (Table 5.1), although not the DSG2 promoter (Table 5.2).   The AP1 
transcription factor is made up of basic leucine zipper proteins from the Fos 
families (c-fos, FosB, Fra-1 and Fra-2) and the Jun families (c-Jun, JunB and 
JunD) which join together as either homodimers or heterodimers, to yield a 
variety of responses.  It has been implicated in cell cycle control, cell 
proliferation and apoptosis, as well as malignant transformation and 
resistance to chemotherapeutic agents in colorectal cancer (Ashida, 
Tominaga et al. 2005).   
 
When co-transfected into Caco2 cells with DSC2 reporter constructs both c-
fos and JunB had a significant activating effect (Fig 5.8).  c-Jun caused a 5.5-
fold activation of the DSC2(1kb) promoter and a 2.5–fold activation of the 
DSC2(500) promoter.  Truncation of the DSC2 promoter had little effect on 
the transactivating ability of JunB which caused a 3-fold activation of the 
longer DSC2 promoter construct and a 3.2-fold activation of the shorter DSC2 
promoter construct.  The effect of AP1 factors on the DSG2 promoter was 
less dramatic with c-fos and c-jun, but not JunB, causing moderate (<2-fold) 
increases in transcriptional activity.   
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Fig 5.8 Effect of AP1 transcription factors on DSC2 and DSG2 promoter 
activity  
 
 
Luciferase reporter plasmids were co-transfected into Caco2 cells with either  
empty expression plasmid pcDNA3 or pcDNA3 plus C/EBP c-fos, c-jun or 
JunB.   Activity is shown relative to the empty vector pcDNA3, which has been 
given a reference value of 1. *p<0.05. 
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5.9 Effect of activator protein-2 (AP2) and activator protein-4 (AP4) 
transcription factors on DSC2 and DSG2 promoter activity  
Putative binding sites for transcription factor AP2 were located in both the 
DSC2 and DSG2 promoters by the MatInspector programme (Tables 5.1 and 
5.2).  A number of potential binding sites for the AP4 transcription factor were 
also located in the DSC2, but not the DSG2 promoter.  AP2 is involved in the 
regulation of cell proliferation, differentiation and apoptosis, and has been 
implicated in the development of cancer.  AP2α is thought to act as a tumour 
suppressor in many cancers and it is thought that AP2γ may act as a 
prognostic marker in testicular cancer (Pellikainen and Kosma, 2007).  AP4 is 
a transcription factor normally only expressed in the non-differentiated, 
proliferative progenitor compartment of colonic crypts.  Expression of AP4 has 
been shown to correlate with colorectal cancer progression and the presence 
of lymph node metastasis (Cao, Tang et al. 2009).   
 
Both AP2α and AP2γ were shown to stimulate the DSC2 promoter, causing a 
3.3-fold and a 5.2-fold increase in luciferase activity (Fig 5.9).  The 
transactivating effect was lost when the distal 500 bases of the promoter were 
deleted.  AP4 had no effect on the DSC2 promoter, despite a number of 
putative AP4 sites being identified by the MatInspector programme.  A similar 
pattern was seen with the DSG2 constructs, with AP2α and AP2ɣ causing 2.9- 
and 2.7-fold increases in luciferase activity respectively with the longer 
promoter construct.  In the case of the DSG2 promoter AP4 did stimulate a 
2.4-fold increase in activity with the longer construct, presumably through 
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binding to a site not identified by MatInspector.  This effect was maintained in 
the shorter construct. 
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Fig 5.9 Effect of AP2 and AP4 on DSC2 and DSG2 promoter activity 
 
 
 
 
Luciferase reporter plasmids were co-transfected into Caco2 cells with either  
empty expression plasmid pcDNA3 or pcDNA3 plus AP2α, AP2γ or AP4 
cDNAs.   Activity is shown relative to the empty vector pcDNA3, which has 
been given a reference value of 1. *p<0.05.   
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5.10 Effect of β-catenin, plakoglobin and p53 on DSC2 and DSG2 
promoter activity  
 
The T-cell factor/Lymphoid enhancing factor-1 (Tcf/Lef) family is a group of 
transcription factors that form complexes with β-catenin, an Armadillo family 
member that plays a key role in the Wnt signalling pathway (Behrens, von 
Kries et al. 1996; van de Wetering, Cavallo et al. 1997).  Tcf/Lef-β-catenin 
complexes activate transcription and failure to degrade β-catenin is 
associated with the development of most colorectal tumours (Morin, Sparks et 
al. 1997).  Plakoglobin is related to β-catenin and interacts with many of the 
same proteins.  However, its role in Wnt/β-catenin signalling is less well 
defined; the possibility exists that plakoglobin may act as both a positive and 
negative regulator of Wnt signalling (Chidgey and Dawson, 2007).  The 
tumour suppressor gene, p53 is located on chromosome 17p, a location often 
lost or altered in many malignancies, including colorectal cancer (Vogelstein, 
Fearon et al. 1988).  It has numerous roles as a transcriptional regulator and 
has been shown to regulate desmocollin gene expression in both breast and 
colorectal cancer cells (Oshiro, Watts et al. 2003; Cui, Chen et al. 2011).   
 
A small but significant 1.7-fold activation of the DSC2 promoter was achieved 
by transient transfection of Caco2 cells with β-catenin (Fig 5.10).  As β-
catenin acts in concert with Tcf/Lef family members, the cells were 
additionally transfected with Lef1, which had no significant effect on its own 
(data not shown).  The transactivating effect of β-catenin was maintained 
when the experiment was repeated with the shorter DSC2 promoter plasmid.  
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Co-transfection of plakoglobin and Lef1 had no significant effect on luciferase 
activity.  Significant repression of the DSC2 promoter was obtained with p53 
although this effect was lost with DSC2(500) construct (Fig 5.10).  This was 
somewhat surprising given that a number of putative p53 binding sites were 
located by the MatInspector programme in the proximal DSC2 promoter 
(Table 5.1). 
 
Both β-catenin (1.6-fold) and plakoglobin (1.4-fold) had a modest 
transactivating effect on the longer DSG2 promoter construct (Fig.5.10).  The 
transactivating effect was maintained and somewhat enhanced when the 
shorter reporter construct was used.  As with DSC2, DSG2 promoter activity 
appears to be repressed by p53.  This effect was attenuated with the shorter 
promoter construct. 
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Fig 5.10 Effect of β-catenin, plakoglobin and p53 on DSC2 and DSG2 
promoter activity 
 
Luciferase reporter plasmids were co-transfected into Caco2 cells with either  
empty expression plasmid pcDNA3 or pcDNA3 plus β-catenin, plakoglobin or 
p53 cDNAs.  In experiments with β-catenin and plakoglobin cells were 
additionally transfected with pcDNA3 plus cDNA encoding Lef1.  Activity is 
shown relative to the empty vector pcDNA3, which has been given a 
reference value of 1. *p<0.05. 
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5.11 Discussion 
The experiments of chapter 2 demonstrated that DSC2 and DSG2 expression 
is lost in colorectal cancer, and that other desmosomal cadherins (DSC1, 
DSC3, DSG1, and DSG3) are aberrantly expressed.  One potential 
explanation for these observations is that changes in desmosomal cadherin 
gene expression occur as a result of abnormal expression of transcription 
factors in colorectal cancer.  The experiments described in this chapter were 
designed primarily to identify transcription factors that regulate desmosomal 
cadherin gene expression in colonic epithelial cells.  The C/EBP family of 
transcription factors provide the starting place for this investigation as they 
have previously been shown to play a role in the regulation of murine Dsc1 
and Dsc3 gene expression in keratinocytes (Smith, Zhu et al. 2004). 
 
The C/EBPs belong to the basic leucine zipper class of transcription factors, 
and consist of an activation domain, a DNA-binding basic region and a 
leucine-rich dimerisation domain (Agre, Johnson et al. 1989).  Dimerisation 
takes place via the leucine zipper, to form partnerships between the C/EBP 
family members, as well as with other transcription factor families, such as 
NFΚB and the AP1 factors (Vinson, Hai et al. 1993).  Dimerisation is essential 
to the DNA binding process (Landschulz, Johnson et al. 1989), but the  ability 
of hetero- and homo-dimers to  transactivate is variable  (Poli, Mancini et al. 
1990; Kinoshita, Akira et al. 1992).   
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The current study demonstrated for the first time that the DSC2 and DSG2 
promoters, in common with the Dsc1 and Dsc3 promoters (Smith, Zhu et al. 
2004), are transactivated by C/EBPs.  In mouse keratinocytes Dsc1 is most 
strongly activated by C/EBPα, whereas Dsc3 is most strongly activated by 
C/EBPβ (Smith, Zhu et al. 2004).  In human Caco2 cells the DSC2 and DSG2 
promoters are most strongly activated by C/EBPβ.  Both C/EBPα and C/EBPβ 
have very strong transactivating effects on the murine Dsc3 promoter in 
Caco2 cells, although whether the same is true of human DSC3 promoter 
remains to be seen.  High levels of C/EBPβ have been observed in  colorectal 
cancer (Rask, Thörn et al. 2000) and it is conceivable that it is responsible for 
the de novo expression of DSC3 observed in colorectal cancer specimens 
(chapter 3) although much more work will be required to definitively prove that 
there is a causal link between the two. 
  
Other than C/EBPs, a number of other transcription factors were identified 
that could be important in the regulation of desmosomal cadherin gene 
expression in colorectal cells.  Of these the effect of c-jun and AP2ɣ on the 
DSC2 promoter was the most dramatic (Fig 5.8 and Fig 5.9).  Neither of these 
transcription factors has been previously implicated in the regulation of 
desmosomal cadherin gene expression and further investigation would be 
required (see below) to confirm their role. Interestingly, of the transcription 
factors tested only p53 repressed transcription from the DSC2 and DSG2 
promoters (Fig 5.10).  Loss of p53 expression, a frequent event in colorectal 
cancers, might therefore be expected to result in an increase in DSC2 and 
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DSG2 expression, the opposite of our findings in Chapter 2.  Nevertheless it 
would be interesting to determine the effect of p53 on other desmosomal 
cadherin promoters, particularly DSC3 which has been previously identified as 
a p53-target gene (Oshiro, Watts et al., 2003; Cui, Chen et al., 2011). 
 
Clearly much of the work described in this chapter is of a preliminary nature 
and much more experimental data are required.  Confirmation of a role for 
C/EBPs, and other transcription factors such as c-jun and AP2ɣ, in the 
regulation of desmosomal cadherin gene expression could be obtained using 
techniques such as electrophoretic mobility shift assays (EMSA) and 
chromatin immunoprecipitation (ChIP) assays.  EMSA assays can be used to 
confirm whether transcription factors are able to bind to particular sequences 
of DNA (such as those identified in the DSC2 and DSG2 promoters by the 
MatInspector programme) in vitro.  ChIP assays can be used to determine 
whether transcription factors such as the C/EBPs are able to interact with 
desmosomal cadherin promoters in vivo.  Further reporter assays could be 
carried out with mutated promoter sequences to confirm the importance of 
putative binding sites in promoter regions.   
 
It would be interesting to examine the expression patterns of C/EBPs, 
particularly C/EBPα and C/EBPβ in colorectal cancer specimens, and to 
examine the role of C/EBPs on human, as opposed to murine, promoters in 
colorectal cells.  It may be that other mechanisms are responsible for 
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silencing DSC2 and DSG2 expression in colonic cancer cells.  The 
mechanism by which many genes are silenced in colorectal cancer is by 
hypermethylation of CpG islands which are abundant in the promoter regions 
of some genes.  The DSC2 promoter contains a 500bp CpG island (Marsden, 
Collins et al., 1997) so it would be useful to examine the methylation status of 
DSC2, and other desmosomal genes, in colorectal cancer.   
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CHAPTER 6 
DISCUSSION 
 
6.1 Introduction 
This investigation has shown for the first time altered desmocollin expression 
in colorectal cancer.  At the protein level two distinct changes were observed, 
namely loss of desmocollin 2, together with gain of expression of desmocollin 
1 and desmocollin 3, desmosomal cadherins not normally expressed in 
colonic mucosa.  At the transcriptional level no change was observed in DSC2 
mRNA.  However, the gain of expression of DSC1 and DSC3 was 
accompanied by increased message levels.  Desmoglein protein levels were 
not examined but increased levels of mRNA encoding desmogleins not 
normally expressed in colonic mucosa (i.e. DSG1, DSG3 and DSG4) were 
observed, although there was no change in levels of mRNA encoding DSG2, 
the desmoglein normally expressed in colonic mucosa.  An attempt was made 
to investigate the effects of loss of desmosomal cadherin gene expression on 
the behaviour of cultured cells, and potential mechanisms that could account 
for the changes in gene expression were explored.  The aim of this final 
chapter is to discuss these findings in the context of current evidence and 
knowledge of the role of desmosomal cadherins in colorectal cancer, as well 
as to consider future avenues of investigation. 
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6.2 Changes in desmocollin and desmoglein gene expression in 
colorectal cancer 
 
6.2.1 Changes in protein expression 
Changes in desmocollin expression patterns in colorectal cancer may result in 
significant alterations in desmosome function.  In the healthy colonic mucosa, 
DSC2 and DSG2 (Nuber, Schafer et al. 1995) are the only desmosomal 
cadherins that are expressed and therefore loss of these adhesion molecules 
could manifest itself as altered behaviour of colonic cells.  Loss of DSG2-
mediated adhesion has been shown to interfere with intestinal epithelial 
barrier function, altering gut permeability and potentially allowing pathogens to 
translocate systemically (Schlegel, Meir et al. 2010).  Other cancers have 
demonstrated loss of desmosomal components, which may correlate with 
disease progression.  For example, reduced DSC2 expression correlates with 
poor prognosis in pancreatic adenocarcinoma (Hamidov, Altendorf-Hofmann 
et al. 2012).  
 
Three changes in desmosomal cadherin protein expression were observed in 
this series of experiments: reduced DSC2 expression; redistribution of DSC2 
away from the cell surface to the cytoplasm; and expression of DSC1 and 
DSC3, which are not normally expressed in the colonic epithelium. Although 
reduced DSC2 protein expression was observed in colorectal cancer samples 
this was not due to decreased transcription, as the DSC2 mRNA was 
unchanged in the majority of samples examined.  It may be that DSC2 protein 
is lost because of decreased rates of protein synthesis or increased protein 
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degradation.  Loss of protein stability as a result of mutations is one possibility 
although it should be noted that no mutations in desmocollins have been 
documented in colorectal or any other type of cancer.  Several studies have 
shown desmogleins and desmocollins to be targeted by caspases and matrix 
metalloproteinases during desmosome breakdown (Weiske, Schoeneberg et 
al. 2001; Cirillo, Lanza et al. 2008; Kami, Chidgey et al. 2009), and it may be 
that dysregulation of this system in colorectal cancer results in loss of DSC2 
protein.   
 
Drawing a comparison with the classical cadherins, loss of E-cadherin during 
TGF/Mitogen activated protein kinase (MAPK)-induced epithelial-
mesenchymal transition (EMT) not only takes place through reduced 
transcription but also by post-translational mechanisms including 
internalisation and endocytosis (Janda, Nevolo et al. 2006).  Protein kinase C 
has also been shown to lead to the internalisation of classical cadherins (Le, 
Joseph et al. 2002) and given that PKC is thought to be involved in 
desmosome remodelling (Wallis, Lloyd et al. 2000), it is possible that the 
relocalisation of desmosomal cadherins seen in this study is due to similar 
processes.   In addition,  tyrosine phosphorylation of DSG2, as seen in cells 
over-expressing the epidermal growth factor receptor (EGFR), has been 
shown to result in reduced levels of both DSG2 and DSC2 at the cell 
membrane, whilst increasing the internalised pool of desmosomal cadherins 
(Lorch, Klessner et al. 2004).  Furthermore, Windoffer et al observed that 
desmosome stability was diminished when extracellular calcium was reduced 
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and that DSC2 was translocated from the cell membrane to the cytoplasm, 
where it remained (Windoffer, Borchert-Stuhltrager et al. 2002).  Even when 
the calcium levels were restored, it appears that the desmosomal cadherins 
previously engaged in desmosome formation are not re-utilised, suggesting 
that a new source of desmosomal cadherins is made available to support 
desmosome formation.  Studies investigating the assembly and stability of 
desmosomal components have shown desmosomal cadherins to be much 
more stable when incorporated into desmosomes and when free, are rapidly 
are rapidly degraded (Pasdar and Nelson 1989). 
 
De novo DSC1 and DSC3 staining was observed both at the cell membrane 
and in the cell cytoplasm. It may be that these desmocollins simply replace 
DSC2 in terms of its adhesive function. However, an alternative explanation 
could be that rather than acting as a compensatory mechanism, the presence 
of DSC1 and DSC3 at the cell membrane may lead to the three desmocollins 
‘competing’ with each other to be incorporated in the junctional structure, 
which could result in DSC2 being displaced from the desmosome, relocalised 
to the cytoplasm and degraded by endocytosis. It is not known whether the 
three desmocollins are equally adhesive, or whether there are subtle 
differences in adhesive function that could lead to changes in cell behaviour.  
Incorporation of different isoforms into desmosomes appears to be isoform-
dependent and can lead not only to desmosome dissociation but also to 
alterations in plakoglobin expression (Ishii, Norvell et al. 2001).   
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The immunohistochemistry study also showed that all samples with 
decreased DSC2 expression exhibited diminished E-cadherin expression 
(Khan, Hardy et al. 2006). E-cadherin is a classical transmembrane cadherin 
found in adherens junctions. It has a well-established tumour suppressor role, 
with loss of E-cadherin function having been demonstrated in gastric cancer, 
invasive lobular breast cancer, prostate and colorectal cancer (Hirohashi 
1998; Kuphal and Behrens 2006). Communication between adherens 
junctions and desmosomes takes place during development, with E-cadherin 
directing desmosome formation (Gumbiner, Stevenson et al. 1988).  
Plakoglobin is thought to mediate this cross-talk as it has been shown to 
incorporate into both desmosomes and adherens junctions (Lewis, Wahl et al. 
1997). E-cadherin expression is thought to contribute to the stability of 
desmosomal cadherins, which are rapidly degraded when cell contacts are 
diminished (Penn, Burdett et al. 1987) so it may be that loss of E-cadherin in 
colorectal cancer may cause disruption of desmosomes.  However the 
relationship appears to be co-operative, as desmosomal components also 
contribute to the formation of mature adherens junctions (Vasioukhin, Bowers 
et al. 2001).  Coordinated expression of both adherens junctions and 
desmosomes is able to significantly strengthen intercellular adhesion 
(Getsios, Huen et al. 2004) and it may be that both are required to prevent 
changes in cell behaviour. 
 
Desmosomal adhesion differs from that exhibited by adherens junctions.  In 
tissues or cells that have been cultured for long periods desmosomes are able 
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to achieve a hyper-adhesive state in which they become stable even in the 
absence of extracellular calcium (Borysenko and Revel 1973; Kimura, Merritt 
et al. 2007).    Adherens junctions are unable to achieve a hyperadhesive 
state and remain sensitive to extracellular calcium levels, even after 
prolonged periods of cell-cell contact.  Calcium-induced cell contact has been 
shown to increase the metabolic stability of some of the  individual 
desmosomal components, including desmogleins (Pasdar and Nelson 1989)   
In turn, this may influence the stability of other components, as the 
degradation of plakoglobin is greatly reduced by co-expression of 
desmogleins and desmocollins (Kowalczyk, Palka et al. 1994).  The switch 
between the hyperadhesive calcium-independent state and a calcium-
dependent state has been observed as a response to wounding (Garrod, 
Berika et al. 2005) and is thought to be mediated by protein kinase C (Wallis, 
Lloyd et al. 2000). By allowing desmosomes to disassemble and migrate into 
the wound, PKC facilitates epithelial remodelling and repair. Although PKC 
has been shown to reduce colonic cell proliferation via suppression of β-
catenin signalling (Gwak, Jung et al. 2009), it also is able to promote 
desmosome assembly in an  α-catenin deficient colon cancer cell line 
(Hengel, Gohon et al. 1997). 
 
The desmocollins are thought to have an early role in desmosome assembly, 
reaching the cell surface before desmogleins (Burdett and Sullivan 2002).  
Furthermore, in keeping with the observations that desmosomal components 
influence adherens junction assembly, loss of DSC3 function appears to 
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interfere with both desmosome and adherens junction formation, whereas 
loss of DSG3 function only affects desmosomes (Hanakawa, Amagai et al. 
2000).  Therefore DSC2 loss, as demonstrated in this investigation may affect 
intercellular adhesion mediated by both desmosomes and adherens junctions. 
 
 
6.2.2 Changes in mRNA expression 
Despite the reduction of DSC2 protein, no loss of DSC2 mRNA expression 
was observed.  However, de novo expression of DSC1 and DSC3 mRNA was 
identified in the tumour samples studied.   As discussed previously, all 
desmosomal cadherins lie close together on chromosome 18q and share 
significant sequence homology (Hunt, Sahota et al. 1999).  Expression of the 
different isoforms within a tissue appears to take place in a coordinated 
fashion (King, Angst et al. 1997; Smith, Zhu et al. 2004) suggesting these 
events are linked.  Loss of DSC2 protein may trigger a compensatory 
activation of DSC1 and DSC3 gene transcription (Hanakawa, Matsuyoshi et 
al. 2002).  In support of this idea it has been shown that Dsc2 mRNA is 
upregulated in the Dsc1 knockout mouse (M Chidgey, unpublished), although 
in the case of the knockout mice the increase in Dsc2 mRNA was not 
translated into a significant increase in Dsc2 protein levels (Chidgey, 
Brakebusch et al. 2001).  It should be noted that de novo expression of DSC1 
and DSC3 were seen in some samples which appeared to have the normal 
amount of DSC2 protein product, suggesting that as simple feedback 
mechanism is unlikely to be the entire story. 
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De novo expression of the desmosomal cadherins DSC1 and DSC3 in 
colorectal cancer cells could have unexpected consequences.  Inappropriate 
expression of Dsc3 in the suprabasal layers of transgenic mouse epidermis (it 
is normally expressed in basal cell layers) has been shown to increase β-
catenin transcriptional activity (Hardman, Liu et al. 2005).  Similarly, Dsg3 
misexpression in suprabasal layers resulted in hyperproliferation and 
abnormal differentiation of the epidermis (Merritt, Berika et al. 2002).  
Moreover, suprabasal misexpression of Dsg2 in the epidermis of transgenic 
mice had profound effects - hyperproliferative skin, resistance to apoptosis 
and activation of cell signalling pathways (Brennan, Hu et al. 2007).  The 
possible consequences that loss of DSC2, and gain of DSC1 and DSC3, may 
have on the behaviour of colonic epithelial cells in colorectal cancer remain to 
be determined but it is a fascinating area for future investigation.  However, on 
a cautionary note it should be remembered that in one experiment 
misexpression of Dsc1 in the basal layer of the epidermis resulted in its 
incorporation into basal layer desmosomes without an obvious change in skin 
phenotype.  Thus it may be that Dsc1 and Dsc3 have identical functions, at 
least in the basal layers of the skin (Henkler, Strom et al. 2001).   
   
In general, the increases in mRNA expression were much greater in the 
desmogleins than in the desmocollins.  This could have profound 
consequences if the large increases in desmoglein mRNAs were 
accompanied but similarly large increases in functional desmoglein protein.   
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Alterations in the relative expression of DSG1 to DSC1 have been shown to 
alter desmosomal adhesion (Getsios, Amargo et al. 2004). This change in 
stoichiometry may result in different DSC-DSG pairings, or indeed alterations 
in cell signalling.  Desmogleins have a much greater affinity for binding to 
plakoglobin than desmocollins (Chitaev, Leube et al. 1996; Kowalczyk, 
Borgwardt et al. 1996), so changes in stoichiometry could affect intracellular 
signal transduction pathways (Kolligs, Kolligs et al. 2000).   
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6.3 Cadherin switching in cancer 
The epithelial-mesenchymal transition is a biological process that takes place 
during embryonic development (Thiery 2003), but also in disease (Thiery 
2002).  EMT is characterised by loss of E-cadherin expression and gain of 
expression of the ‘mesenchymal’ cadherin N-cadherin.  Activation of tyrosine 
kinases, expression of zinc finger binding proteins such as Snail and Slug, 
and activation of matrix metalloproteinase activity (Sipos and Galamb 2012) 
are all characteristics of EMT.  In cancer EMT it has been shown to contribute 
to increased motility of tumour cells and increased invasive potential 
(Agiostratidou, Hulit et al. 2007).  The role of EMT has been demonstrated in 
the development of colonic disease.  Loss of E-cadherin expression, 
accompanied by gain of P-cadherin expression, has been documented in 
radiation proctitis and early colorectal neoplasia (Hardy, Brown et al. 2002; 
Hardy, Tselepis et al. 2002).  Induction of EMT has been implicated in 
progression of colorectal cancer (Gulhati, Cai et al. 2009) and the regulation 
of metastasis (Thiery 2002; Lee, Dedhar et al. 2006) and changes have been 
noted in the TGFβ, Akt and wnt signalling pathways (Rychahou, Kang et al. 
2008). 
 
As a major player in epithelial adhesion, loss of desmosomal adhesion may 
trigger an EMT and drive cancer progression.  A number of factors could 
result in desmosome dissolution and EMT.  The transcription factor Slug, is 
upregulated in EMT and has been shown to cause desmosome dissociation 
(Savagner, Yamada et al. 1997). In addition, both Slug and Snail induce 
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downregulation of DSG2 in ovarian cancer cells (Kurrey, Amit et al. 2005).   
The epidermal growth factor receptor (EGFR) is upregulated in EMT and 
tyrosine phosphorylation of proteins by EGFR is a critical step in the epithelial-
mesenchymal transition (Thiery 2003).  Plakoglobin has been identified as a 
target of the EGFR pathway and tyrosine phosphorylation of desmogleins 
results in their reduced expression and loss of membrane localisation in 
keratinocytes, (Yin, Getsios et al. 2005) and simple epithelial cell lines 
(Miravet, Piedra et al. 2003).  It is noteworthy that EGFR inhibition has also 
been shown to promote desmosome assembly in head and neck cancers, 
with increased expression of DSC2 and DSG2, and this is coincident with a 
change in morphology from fibroblastic to epithelial  (Lorch, Klessner et al. 
2004).  It remains to be seen whether any of these factors are involved in the 
loss of expression of DSC2 that occurs in colorectal cancer, and indeed 
whether loss of DSC2 is able to trigger EMT and cancer.  Whether DSC1 and 
DSC3 act as ‘mesenchymal’ cadherins and promote EMT remains to be 
determined. 
 
6.4 Intracellular signalling 
The changes in desmosomal cadherin expression observed in colorectal 
cancer may affect intracellular signal transduction pathways.  An obvious 
candidate for mediating signals through this route is plakoglobin, which has 
well-established roles as both a structural component of desmosomes and as 
an agent of wnt signalling in colon cancer cells (Kolligs, Kolligs et al. 2000).  It 
is able to behave in a similar manner to β-catenin and is targeted by APC-
proteasome complex for degradation.  The desmosomal cadherins are able to 
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bind directly to plakoglobin, with loss of the desmoglein C-terminal region 
resulting in reduced plakoglobin binding (Chitaev, Averbakh et al. 1998).  
Thus, production of a truncated desmosomal protein product or reduced 
expression may influence plakoglobin-mediated signals.   
 
Although no change in DSC2 mRNA was observed, DSC1 and DSC3 were 
upregulated. The desmocollin isoforms may vary in their plakoglobin binding 
potential.  In addition, the de novo expression of desmoglein mRNAs were far 
higher than those observed for their desmocollin partners.  If this was 
translated into a functional protein, it could be anticipated that there would be 
an excess of desmogleins and that some of this excess protein could be 
released from the membrane into the cytoplasm.  Evidence is emerging that 
non-desmosomal DSG3 is able to engage in cell signalling in keratinocytes 
(Tsang, Liu et al. 2010; Tsang, Brown et al. 2012).  To examine this further it 
would be necessary to establish whether desmoglein proteins are present in 
colorectal cancer samples and to determine whether they co-localise with 
desmocollin protein at the cell membrane or are redistributed to the 
cytoplasm.   This could be achieved by western blotting and 
immunohistochemistry of the tissue samples. 
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6.5 Functional role of desmosomal cadherins in colorectal cancer.   
Cancer is a genetically unstable disease, with multiple events and pathways, 
not all of which contribute to the neoplastic process.  As loss of E-cadherin 
from adherens junctions has a profound effect on the behaviour of cultured 
cells and cancer, it was proposed that the desmosomal cadherins could have 
a similar role. The investigations of chapter 4 sought to establish a potential 
role for desmosomal cadherins in colorectal cancer by antisense knockdown 
of DSC2 and DSG2 mRNA.  Although this strategy was successful in that 
some knockdown of DSC2 and DSG2 mRNA was achieved, the knockdown 
of message levels were not sufficient to manifest as a change at the protein 
level. 
Evidence is now emerging that desmosomal cadherins play a functional role 
in colorectal cancer. By using a small-interfering RNA knockdown technique, 
Kolegraff et al were able to demonstrate a role for DSC2 in β-catenin 
signalling through the P13K/Akt pathway and that this may be mediated by 
EGFR signalling (Kolegraff, Nava et al. 2011).  This study also demonstrated 
that DSC2 knockdown decreased cell proliferation and promotes invasive 
behaviour, supporting the idea of a tumour suppressor role.  However this 
study did not report any changes in expression of the other desmocollins and 
a complementary study of DSG2 knockdown would be very informative. 
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6.6 Transcriptional regulation 
Little is known about the regulation of desmosomal cadherin gene expression.  
It is thought to take place in a coordinated fashion as the genes are clustered 
together on chromosome 18q.  In this investigation, C/EBPβ activated both 
the DSC2 and DSG2 promoters.  Of the other C/EBPs, C/EBPδ had a 
moderate transactivating effect on the DSC2 promoter and both C/EBPs α 
and δ activated the DSG2 promoter.  C/EBPα is considered to have an 
antiproliferative role, following the observations that it is able to mediate cell-
cycle arrest (Umek, Friedman et al. 1991), is expressed in high levels in 
terminally differentiated cells (Birkenmeier, Gwynn et al. 1989; Cao, Umek et 
al. 1991) and is a potent inhibitor of proliferation when overexpressed in 
cultured cells (Hendricks-Taylor and Darlington 1995). In contrast to this, 
C/EBPβ is considered to be pro-proliferative, with high levels of expression 
seen following partial hepatectomy and in several tumours, including 
colorectal cancer (Rask, Thörn et al. 2000) and breast cancer (Milde-
Langosch, Löning et al. 2003).  Interestingly, the C/EBPs had a much greater 
activating effect on the promoters of those desmocollins that are not normally 
expressed in colorectal cells (i.e. DSC1 and DSC3) than on that of DSC2 
which is normally expressed in colorectal cells.  However, it is unlikely that 
changes in C/EBP expression that may occur in colorectal cancer could alone 
explain the changes in desmosomal cadherin expression that we have 
observed (Chapter 3).  Overexpression of, for example, C/EBPβ could be 
responsible for the aberrant expression of DSC3 in particular.  However, one 
might expect that overexpression of C/EBPβ to result in increased DSC2 
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mRNA and protein, neither of which were observed in colorectal cancer 
samples.   
 
6.7 Future directions 
The role of desmosomal cadherins in cancer is increasingly being 
acknowledged and the publication arising from this investigation appears to 
have renewed interest in their role in colorectal cancer.  Of course, these 
experiments are preliminary and beg more questions than they answer.  
There are several avenues to explore. Firstly, from this study, it is not possible 
to say where in the adenoma-carcinoma sequence these changes take place.  
Further samples would have to be studied, including adenomas and cancers 
at all stages of the disease to elucidate the timing of these events.  In addition 
to this, background molecular information could be collected about the tumour 
samples used, in order to investigate whether the observed changes in 
desmosomal cadherin expression can be attributed to a particular molecular 
pathway, namely the chromosomal instability, microsatellite instability or 
serrated pathway. 
 
A second line of investigation could look at DSG2 knockdown using a similar 
strategy to that used for the successful knockdown of DSC2 (Kolegraff, Nava 
et al. 2011).  As part of this, supporting evidence for concomitant upregulation 
of other desmosomal cadherins would also be sought. In addition, stable 
transfection experiments to over-express DSC1, DSC3, DSG1 and DSG3, 
separately or together in colon, as well as other epithelial cell lines, would 
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allow the effects of de novo expression to be investigated, in particular cell 
adhesion and migration.  Transient transfections with the Topflash plasmid 
could allow β-catenin activity to be investigated (Hardman, Liu et al. 2005). 
A third potential line of investigation would be to investigate further the 
transcriptional regulation of desmosomal cadherins in colon cancer cells.  
Confirmation of a role for the C/EBPs, both in colon cancer and desmosomal 
gene regulation, is urgently required.  Recent studies have shown that the 
transcription factors CDX1 and CDX2 are able to regulate DSC2 activity in 
colon cancer cells (Funakoshi, Ezaki et al. 2008).  As discussed earlier, 
desmosomal cadherins have been implicated in EGFR pathways and 
epithelial-mesenchymal transition and the transcription factor Slug causes 
desmosome dissociation (Savagner, Yamada et al. 1997).  The effect of Slug 
and other EMT-regulators such as Snail and Twist on the desmosomal 
cadherin promoter activity would provide a further line of investigation. 
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